<a id="pl.1.3"></a><var>1.3</var>federal controlled substance schedules; modifying the authority of the Board of <br/>
<a id="pl.1.4"></a><var>1.4</var>Pharmacy to regulate controlled substances; providing for penalties;amending Minnesota Statutes 2010, sections 152.02, as amended; 152.18, subdivision 1; Minnesota Statutes 2011 Supplement,
         section 152.027, subdivision 6.<a id="pl.1.7"></a><var>1.7</var>BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:<br/>
<br/>
<a id="bill.0.1.0"></a><a id="pl.1.8"></a><var>1.8</var>    Section 1. Minnesota Statutes 2010, section 152.02, as amended by Laws 2011, chapter <br/>
<a id="pl.1.9"></a><var>1.9</var>53, sections 4 and 5, is amended to read:<br/>
<a id="pl.1.10"></a><var>1.10</var><b>152.02 SCHEDULES OF CONTROLLED SUBSTANCES; </b><br/>
<a id="pl.1.11"></a><var>1.11</var><b>ADMINISTRATION OF CHAPTER.</b><br/>
<a id="pl.1.12"></a><var>1.12</var>    Subdivision 1. <b>Five schedules.</b> There are established five schedules of controlled <br/>
<a id="pl.1.13"></a><var>1.13</var>substances, to be known as Schedules I, II, III, IV, and V. Such The schedules shall <br/>
<a id="pl.1.14"></a><var>1.14</var>initially consist of the substances listed in this section by whatever official name, common <br/>
<a id="pl.1.15"></a><var>1.15</var>or usual name, chemical name, or trade name designated.<br/>
<a id="pl.1.16"></a><var>1.16</var>    Subd. 2. <b>Schedule I.</b> The following items are listed in Schedule I: (a) Schedule I <br/>
<a id="pl.1.17"></a><var>1.17</var>consists of the substances listed in this subdivision.<br/>
<a id="pl.1.18"></a><var>1.18</var>(1) (b) Opiates. Unless specifically excepted or unless listed in another schedule, <br/>
<a id="pl.1.19"></a><var>1.19</var>any of the following substances, including their analogs, isomers, esters, ethers, salts, and <br/>
<a id="pl.1.20"></a><var>1.20</var>salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence <br/>
<a id="pl.1.21"></a><var>1.21</var>of the analogs, isomers, esters, ethers and salts is possible within the specific chemical <br/>
<a id="pl.1.22"></a><var>1.22</var>designation: <br/>
<a id="pl.1.23"></a><var>1.23</var>(1) acetylmethadol; <br/>
<a id="pl.1.24"></a><var>1.24</var>(2) allylprodine; <br/>
<a id="pl.2.1"></a><var>2.1</var>(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as <br/>
<a id="pl.2.2"></a><var>2.2</var>levomethadyl acetate); <br/>
<a id="pl.2.3"></a><var>2.3</var>(4) alphameprodine; <br/>
<a id="pl.2.4"></a><var>2.4</var>(5) alphamethadol;<br/>
<a id="pl.2.5"></a><var>2.5</var>(6) alpha-methylfentanyl benzethidine; <br/>
<a id="pl.2.6"></a><var>2.6</var>(7) betacetylmethadol; <br/>
<a id="pl.2.7"></a><var>2.7</var>(8) betameprodine; <br/>
<a id="pl.2.8"></a><var>2.8</var>(9) betamethadol; <br/>
<a id="pl.2.9"></a><var>2.9</var>(10) betaprodine; <br/>
<a id="pl.2.10"></a><var>2.10</var>(11) clonitazene; <br/>
<a id="pl.2.11"></a><var>2.11</var>(12) dextromoramide; dextrorphan;<br/>
<a id="pl.2.12"></a><var>2.12</var>(13) diampromide; <br/>
<a id="pl.2.13"></a><var>2.13</var>(14) diethyliambutene;<br/>
<a id="pl.2.14"></a><var>2.14</var>(15) difenoxin; <br/>
<a id="pl.2.15"></a><var>2.15</var>(16) dimenoxadol; <br/>
<a id="pl.2.16"></a><var>2.16</var>(17) dimepheptanol; <br/>
<a id="pl.2.17"></a><var>2.17</var>(18) dimethyliambutene; <br/>
<a id="pl.2.18"></a><var>2.18</var>(19) dioxaphetyl butyrate; <br/>
<a id="pl.2.19"></a><var>2.19</var>(20) dipipanone; <br/>
<a id="pl.2.20"></a><var>2.20</var>(21) ethylmethylthiambutene; <br/>
<a id="pl.2.21"></a><var>2.21</var>(22) etonitazene; <br/>
<a id="pl.2.22"></a><var>2.22</var>(23) etoxeridine; <br/>
<a id="pl.2.23"></a><var>2.23</var>(24) furethidine; <br/>
<a id="pl.2.24"></a><var>2.24</var>(25) hydroxypethidine; <br/>
<a id="pl.2.25"></a><var>2.25</var>(26) ketobemidone; <br/>
<a id="pl.2.26"></a><var>2.26</var>(27) levomoramide; <br/>
<a id="pl.2.27"></a><var>2.27</var>(28) levophenacylmorphan;<br/>
<a id="pl.2.28"></a><var>2.28</var>(29) 3-methylfentanyl;<br/>
<a id="pl.2.29"></a><var>2.29</var>(30) acetyl-alpha-methylfentanyl;<br/>
<a id="pl.2.30"></a><var>2.30</var>(31) alpha-methylthiofentanyl;<br/>
<a id="pl.2.31"></a><var>2.31</var>(32) benzylfentanyl beta-hydroxyfentanyl;<br/>
<a id="pl.2.32"></a><var>2.32</var>(33) beta-hydroxy-3-methylfentanyl;<br/>
<a id="pl.2.33"></a><var>2.33</var>(34) 3-methylthiofentanyl;<br/>
<a id="pl.2.34"></a><var>2.34</var>(35) thenylfentanyl; <br/>
<a id="pl.2.35"></a><var>2.35</var>(36) thiofentanyl;<br/>
<a id="pl.2.36"></a><var>2.36</var>(37) para-fluorofentanyl; <br/>
<a id="pl.3.1"></a><var>3.1</var>(38) morpheridine;<br/>
<a id="pl.3.2"></a><var>3.2</var>(39) 1-methyl-4-phenyl-4-propionoxypiperidine; <br/>
<a id="pl.3.3"></a><var>3.3</var>(40) noracymethadol; <br/>
<a id="pl.3.4"></a><var>3.4</var>(41) norlevorphanol;<br/>
<a id="pl.3.5"></a><var>3.5</var>(42)  normethadone;<br/>
<a id="pl.3.6"></a><var>3.6</var>(43) norpipanone;<br/>
<a id="pl.3.7"></a><var>3.7</var>(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP); <br/>
<a id="pl.3.8"></a><var>3.8</var>(45) phenadoxone; <br/>
<a id="pl.3.9"></a><var>3.9</var>(46) phenampromide; <br/>
<a id="pl.3.10"></a><var>3.10</var>(47) phenomorphan; <br/>
<a id="pl.3.11"></a><var>3.11</var>(48) phenoperidine; <br/>
<a id="pl.3.12"></a><var>3.12</var>(49) piritramide; <br/>
<a id="pl.3.13"></a><var>3.13</var>(50) proheptazine; <br/>
<a id="pl.3.14"></a><var>3.14</var>(51) properidine;<br/>
<a id="pl.3.15"></a><var>3.15</var>(52) propiram; <br/>
<a id="pl.3.16"></a><var>3.16</var>(53) racemoramide;<br/>
<a id="pl.3.17"></a><var>3.17</var>(54) tilidine; <br/>
<a id="pl.3.18"></a><var>3.18</var>(55) trimeperidine.<br/>
<a id="pl.3.19"></a><var>3.19</var>(2) (c) Opium derivatives. Any of the following opium derivatives substances, <br/>
<a id="pl.3.20"></a><var>3.20</var>their analogs, salts, isomers, and salts of isomers, unless specifically excepted or unless <br/>
<a id="pl.3.21"></a><var>3.21</var>listed in another schedule, whenever the existence of the analogs, salts, isomers and salts <br/>
<a id="pl.3.22"></a><var>3.22</var>of isomers is possible within the specific chemical designation: <br/>
<a id="pl.3.23"></a><var>3.23</var>(1) acetorphine; <br/>
<a id="pl.3.24"></a><var>3.24</var>(2) acetyldihydrocodeine; acetylcodone; <br/>
<a id="pl.3.25"></a><var>3.25</var>(3) benzylmorphine; <br/>
<a id="pl.3.26"></a><var>3.26</var>(4) codeine methylbromide; <br/>
<a id="pl.3.27"></a><var>3.27</var>(5) codeine-n-oxide; <br/>
<a id="pl.3.28"></a><var>3.28</var>(6) cyprenorphine; <br/>
<a id="pl.3.29"></a><var>3.29</var>(7) desomorphine; <br/>
<a id="pl.3.30"></a><var>3.30</var>(8) dihydromorphine;<br/>
<a id="pl.3.31"></a><var>3.31</var>(9)  drotebanol; <br/>
<a id="pl.3.32"></a><var>3.32</var>(10) etorphine; <br/>
<a id="pl.3.33"></a><var>3.33</var>(11) heroin; <br/>
<a id="pl.3.34"></a><var>3.34</var>(12) hydromorphinol; <br/>
<a id="pl.3.35"></a><var>3.35</var>(13) methyldesorphine; methylhydromorphine<br/>
<a id="pl.3.36"></a><var>3.36</var>(14) methyldihydromorphine; <br/>
<a id="pl.4.1"></a><var>4.1</var>(15) morphine methylbromide;<br/>
<a id="pl.4.2"></a><var>4.2</var>(16) morphine methylsulfonate; <br/>
<a id="pl.4.3"></a><var>4.3</var>(17) morphine-n-oxide; <br/>
<a id="pl.4.4"></a><var>4.4</var>(18) myrophine; <br/>
<a id="pl.4.5"></a><var>4.5</var>(19) nicocodeine; <br/>
<a id="pl.4.6"></a><var>4.6</var>(20) nicomorphine; <br/>
<a id="pl.4.7"></a><var>4.7</var>(21) normorphine; <br/>
<a id="pl.4.8"></a><var>4.8</var>(22) pholcodine; <br/>
<a id="pl.4.9"></a><var>4.9</var>(23) thebacon.<br/>
<a id="pl.4.10"></a><var>4.10</var>(3) (d) Hallucinogens. Any material, compound, mixture or preparation which <br/>
<a id="pl.4.11"></a><var>4.11</var>contains any quantity of the following hallucinogenic substances, their analogs, salts, <br/>
<a id="pl.4.12"></a><var>4.12</var>isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically <br/>
<a id="pl.4.13"></a><var>4.13</var>excepted or unless listed in another schedule, whenever the existence of the analogs, salts, <br/>
<a id="pl.4.14"></a><var>4.14</var>isomers, and salts of isomers is possible: <br/>
<a id="pl.4.15"></a><var>4.15</var>3,4-methylenedioxy amphetamine (1) methylenedioxy amphetamine; <br/>
<a id="pl.4.16"></a><var>4.16</var>3,4-methylenedioxymethamphetamine (2) methylenedioxymethamphetamine;<br/>
<a id="pl.4.17"></a><var>4.17</var>(3) methylenedioxy-N-ethylamphetamine (MDEA);<br/>
<a id="pl.4.18"></a><var>4.18</var>(4) n-hydroxy-methylenedioxyamphetamine; <br/>
<a id="pl.4.19"></a><var>4.19</var>(5) 4-bromo-2,5-dimethoxyamphetamine (DOB); <br/>
<a id="pl.4.20"></a><var>4.20</var>(6) 2,5-dimethoxyamphetamine (2,5-DMA); <br/>
<a id="pl.4.21"></a><var>4.21</var>(7) 4-methoxyamphetamine; <br/>
<a id="pl.4.22"></a><var>4.22</var>(8) 5-methoxy-3, 4-methylenedioxy amphetamine;<br/>
<a id="pl.4.23"></a><var>4.23</var>(9) alpha-ethyltryptamine; <br/>
<a id="pl.4.24"></a><var>4.24</var>(10) bufotenine; <br/>
<a id="pl.4.25"></a><var>4.25</var>(11) diethyltryptamine; <br/>
<a id="pl.4.26"></a><var>4.26</var>(12) dimethyltryptamine; <br/>
<a id="pl.4.27"></a><var>4.27</var>(13) 3,4,5-trimethoxy amphetamine; <br/>
<a id="pl.4.28"></a><var>4.28</var>(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM); <br/>
<a id="pl.4.29"></a><var>4.29</var>(15) ibogaine; <br/>
<a id="pl.4.30"></a><var>4.30</var>(16) lysergic acid diethylamide (LSD); marijuana; <br/>
<a id="pl.4.31"></a><var>4.31</var>(17) mescaline;<br/>
<a id="pl.4.32"></a><var>4.32</var>(18) parahexyl; <br/>
<a id="pl.4.33"></a><var>4.33</var>(19) N-ethyl-3-piperidyl benzilate; <br/>
<a id="pl.4.34"></a><var>4.34</var>(20) N-methyl-3-piperidyl benzilate; <br/>
<a id="pl.4.35"></a><var>4.35</var>(21) psilocybin; <br/>
<a id="pl.4.36"></a><var>4.36</var>(22) psilocyn; <br/>
<a id="pl.5.1"></a><var>5.1</var>Tetrahydrocannabinols; 1-(1-(2-thienyl) cyclohexyl) piperidine (23) tenocyclidine <br/>
<a id="pl.5.2"></a><var>5.2</var>(TPCP or TCP); <br/>
<a id="pl.5.3"></a><var>5.3</var>(24) N-ethyl-1-phenyl-cyclohexylamine (PCE); <br/>
<a id="pl.5.4"></a><var>5.4</var>(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy); <br/>
<a id="pl.5.5"></a><var>5.5</var>(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);<br/>
<a id="pl.5.6"></a><var>5.6</var>(27) 4-chloro-2,5-dimethoxyamphetamine (DOC); <br/>
<a id="pl.5.7"></a><var>5.7</var>(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);<br/>
<a id="pl.5.8"></a><var>5.8</var>(29) 4-iodo-2,5-dimethoxyamphetamine (DOI); <br/>
<a id="pl.5.9"></a><var>5.9</var>(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B); <br/>
<a id="pl.5.10"></a><var>5.10</var>(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C); <br/>
<a id="pl.5.11"></a><var>5.11</var>(32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD); <br/>
<a id="pl.5.12"></a><var>5.12</var>2,5-dimethoxy-4-ethylphenethylamine, also known as (33) <br/>
<a id="pl.5.13"></a><var>5.13</var>4-ethyl-2,5-dimethoxyphenethylamine (2C-E); <br/>
<a id="pl.5.14"></a><var>5.14</var>2,5-dimethoxy-4-iodophenethylamine, also known as (34) <br/>
<a id="pl.5.15"></a><var>5.15</var>4-iodo-2,5-dimethoxyphenethylamine (2C-I); <br/>
<a id="pl.5.16"></a><var>5.16</var>(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);<br/>
<a id="pl.5.17"></a><var>5.17</var>(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);<br/>
<a id="pl.5.18"></a><var>5.18</var>(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);<br/>
<a id="pl.5.19"></a><var>5.19</var>(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine <br/>
<a id="pl.5.20"></a><var>5.20</var>(2-CB-FLY);<br/>
<a id="pl.5.21"></a><var>5.21</var>(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);<br/>
<a id="pl.5.22"></a><var>5.22</var>(40) alpha-methyltryptamine (AMT);<br/>
<a id="pl.5.23"></a><var>5.23</var>(41) N,N-diisopropyltryptamine (DiPT);<br/>
<a id="pl.5.24"></a><var>5.24</var>(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);<br/>
<a id="pl.5.25"></a><var>5.25</var>(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);<br/>
<a id="pl.5.26"></a><var>5.26</var>(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);<br/>
<a id="pl.5.27"></a><var>5.27</var>(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);<br/>
<a id="pl.5.28"></a><var>5.28</var>(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);<br/>
<a id="pl.5.29"></a><var>5.29</var>(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);<br/>
<a id="pl.5.30"></a><var>5.30</var>(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);<br/>
<a id="pl.5.31"></a><var>5.31</var>(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);<br/>
<a id="pl.5.32"></a><var>5.32</var>(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);<br/>
<a id="pl.5.33"></a><var>5.33</var>(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);<br/>
<a id="pl.5.34"></a><var>5.34</var>(52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);<br/>
<a id="pl.5.35"></a><var>5.35</var>(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);<br/>
<a id="pl.5.36"></a><var>5.36</var>(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);<br/>
<a id="pl.6.1"></a><var>6.1</var>(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);<br/>
<a id="pl.6.2"></a><var>6.2</var>(56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT);<br/>
<a id="pl.6.3"></a><var>6.3</var>(57) methoxetamine (MXE);<br/>
<a id="pl.6.4"></a><var>6.4</var>(58) 5-iodo-2-aminoindane (5-IAI);<br/>
<a id="pl.6.5"></a><var>6.5</var>(59) 5,6-methylenedioxy-2-aminoindane (MDAI).<br/>
<a id="pl.6.6"></a><var>6.6</var>(4) (e) Peyote, providing. All parts of the plant presently classified botanically as <br/>
<a id="pl.6.7"></a><var>6.7</var>Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract <br/>
<a id="pl.6.8"></a><var>6.8</var>from any part of the plant, and every compound, manufacture, salts, derivative, mixture, <br/>
<a id="pl.6.9"></a><var>6.9</var>or preparation of the plant, its seeds or extracts. The listing of peyote as a controlled <br/>
<a id="pl.6.10"></a><var>6.10</var>substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious <br/>
<a id="pl.6.11"></a><var>6.11</var>ceremonies of the American Indian Church, and members of the American Indian Church <br/>
<a id="pl.6.12"></a><var>6.12</var>are exempt from registration. Any person who manufactures peyote for or distributes <br/>
<a id="pl.6.13"></a><var>6.13</var>peyote to the American Indian Church, however, is required to obtain federal registration <br/>
<a id="pl.6.14"></a><var>6.14</var>annually and to comply with all other requirements of law.<br/>
<a id="pl.6.15"></a><var>6.15</var>(5) (f) Central nervous system depressants. Unless specifically excepted or unless <br/>
<a id="pl.6.16"></a><var>6.16</var>listed in another schedule, any material compound, mixture, or preparation which contains <br/>
<a id="pl.6.17"></a><var>6.17</var>any quantity of the following substances having a depressant effect on the central nervous <br/>
<a id="pl.6.18"></a><var>6.18</var>system, including its, their analogs, salts, isomers, and salts of isomers whenever the <br/>
<a id="pl.6.19"></a><var>6.19</var>existence of the analogs, salts, isomers, and salts of isomers is possible within the specific <br/>
<a id="pl.6.20"></a><var>6.20</var>chemical designation:<br/>
<a id="pl.6.21"></a><var>6.21</var>(1) mecloqualone;<br/>
<a id="pl.6.22"></a><var>6.22</var>(2) methaqualone;<br/>
<a id="pl.6.23"></a><var>6.23</var>(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;<br/>
<a id="pl.6.24"></a><var>6.24</var>(4) flunitrazepam.<br/>
<a id="pl.6.25"></a><var>6.25</var>(6) (g) Stimulants. Unless specifically excepted or unless listed in another schedule, <br/>
<a id="pl.6.26"></a><var>6.26</var>any material compound, mixture, or preparation which contains any quantity of the <br/>
<a id="pl.6.27"></a><var>6.27</var>following substances having a stimulant effect on the central nervous system, including its, <br/>
<a id="pl.6.28"></a><var>6.28</var>their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, <br/>
<a id="pl.6.29"></a><var>6.29</var>salts, isomers, and salts of isomers is possible within the specific chemical designation:<br/>
<a id="pl.6.30"></a><var>6.30</var>    (1) aminorex;<br/>
<a id="pl.6.31"></a><var>6.31</var>(2) cathinone;<br/>
<a id="pl.6.32"></a><var>6.32</var>(3) fenethylline;<br/>
<a id="pl.6.33"></a><var>6.33</var>    (4) methcathinone;<br/>
<a id="pl.6.34"></a><var>6.34</var>(5) methylaminorex;<br/>
<a id="pl.6.35"></a><var>6.35</var>(6) N,N-dimethylamphetamine;<br/>
<a id="pl.6.36"></a><var>6.36</var>(7) N-benzylpiperazine (BZP); <br/>
<a id="pl.7.1"></a><var>7.1</var>4-methylmethcathinone (8) methylmethcathinone (mephedrone); <br/>
<a id="pl.7.2"></a><var>7.2</var>(9) 3,4-methylenedioxy-N-methylcathinone (methylone); <br/>
<a id="pl.7.3"></a><var>7.3</var>4-methoxymethcathinone (10) methoxymethcathinone (methedrone); <br/>
<a id="pl.7.4"></a><var>7.4</var>3,4 - methylenedioxypyrovalerone (11) methylenedioxypyrovalerone  (MDPV);<br/>
<a id="pl.7.5"></a><var>7.5</var>(12) fluoromethcathinone;<br/>
<a id="pl.7.6"></a><var>7.6</var>(13) methylethcathinone (MEC);<br/>
<a id="pl.7.7"></a><var>7.7</var>(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);<br/>
<a id="pl.7.8"></a><var>7.8</var>(15) dimethylmethcathinone (DMMC);<br/>
<a id="pl.7.9"></a><var>7.9</var>(16) fluoroamphetamine;<br/>
<a id="pl.7.10"></a><var>7.10</var>(17) fluoromethamphetamine;<br/>
<a id="pl.7.11"></a><var>7.11</var>(18) α-methylaminobutyrophenone (MABP or buphedrone);<br/>
<a id="pl.7.12"></a><var>7.12</var>(19) β-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone);<br/>
<a id="pl.7.13"></a><var>7.13</var>(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);<br/>
<a id="pl.7.14"></a><var>7.14</var>(21) naphthylpyrovalerone (naphyrone);<br/>
<a id="pl.7.15"></a><var>7.15</var>(22) and any other substance, except bupropion or compounds listed under a <br/>
<a id="pl.7.16"></a><var>7.16</var>different schedule, that is structurally derived from 2-aminopropan-1-one by substitution <br/>
<a id="pl.7.17"></a><var>7.17</var>at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not <br/>
<a id="pl.7.18"></a><var>7.18</var>the compound is further modified in any of the following ways:<br/>
<a id="pl.7.19"></a><var>7.19</var>(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, <br/>
<a id="pl.7.20"></a><var>7.20</var>haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring <br/>
<a id="pl.7.21"></a><var>7.21</var>system by one or more other univalent substituents;<br/>
<a id="pl.7.22"></a><var>7.22</var>(ii) by substitution at the 3-position with an acyclic alkyl substituent;<br/>
<a id="pl.7.23"></a><var>7.23</var>(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or <br/>
<a id="pl.7.24"></a><var>7.24</var>methoxybenzyl groups; or<br/>
<a id="pl.7.25"></a><var>7.25</var>(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.<br/>
<a id="pl.7.26"></a><var>7.26</var>(7) (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless <br/>
<a id="pl.7.27"></a><var>7.27</var>specifically excepted or unless listed in another schedule, any natural or synthetic material, <br/>
<a id="pl.7.28"></a><var>7.28</var>compound, mixture, or preparation that contains any quantity of a substance that is a <br/>
<a id="pl.7.29"></a><var>7.29</var>cannabinoid receptor agonist, including, but not limited to, the following substances and, <br/>
<a id="pl.7.30"></a><var>7.30</var>their analogs, including isomers, whether optical, positional, or geometric; esters;, ethers;, <br/>
<a id="pl.7.31"></a><var>7.31</var>salts;, and salts of isomers, esters, and ethers, whenever the existence of the isomers, <br/>
<a id="pl.7.32"></a><var>7.32</var>esters, ethers, or salts is possible within the specific chemical designation:<br/>
<a id="pl.7.33"></a><var>7.33</var>1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007), <br/>
<a id="pl.7.34"></a><var>7.34</var>(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015), <br/>
<a id="pl.7.35"></a><var>7.35</var>1-Pentyl-3-(1-naphthoyl)indole (JWH-018), 1-hexyl-3-(naphthalen-1-oyl)indole <br/>
<a id="pl.7.36"></a><var>7.36</var>(JWH-019), 1-Butyl-3-(1-naphthoyl)indole (JWH-073), <br/>
<a id="pl.8.1"></a><var>8.1</var>4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-081), <br/>
<a id="pl.8.2"></a><var>8.2</var>4-methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl)methanone <br/>
<a id="pl.8.3"></a><var>8.3</var>(JWH-098), (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone <br/>
<a id="pl.8.4"></a><var>8.4</var>(JWH-200), 7-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone <br/>
<a id="pl.8.5"></a><var>8.5</var>(JWH-164), 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-203), <br/>
<a id="pl.8.6"></a><var>8.6</var>4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-210), <br/>
<a id="pl.8.7"></a><var>8.7</var>2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250), <br/>
<a id="pl.8.8"></a><var>8.8</var>1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), (6aR,10aR)- <br/>
<a id="pl.8.9"></a><var>8.9</var>9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- <br/>
<a id="pl.8.10"></a><var>8.10</var>tetrahydrobenzo[c]chromen-1-ol (HU-210), (R)-(+)-[2,3-Dihydro-5-methyl-3- <br/>
<a id="pl.8.11"></a><var>8.11</var>(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone <br/>
<a id="pl.8.12"></a><var>8.12</var>(WIN-55,212-2), 2-[3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol (CP47,497), <br/>
<a id="pl.8.13"></a><var>8.13</var>dimethylheptylpyran.<br/>
<a id="pl.8.14"></a><var>8.14</var>(1) marijuana;<br/>
<a id="pl.8.15"></a><var>8.15</var>(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, <br/>
<a id="pl.8.16"></a><var>8.16</var>synthetic equivalents of the substances contained in the cannabis plant or in the <br/>
<a id="pl.8.17"></a><var>8.17</var>resinous extractives of the plant, or synthetic substances with similar chemical structure <br/>
<a id="pl.8.18"></a><var>8.18</var>and pharmacological activity to those substances contained in the plant or resinous <br/>
<a id="pl.8.19"></a><var>8.19</var>extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans <br/>
<a id="pl.8.20"></a><var>8.20</var>tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;<br/>
<a id="pl.8.21"></a><var>8.21</var>(3) synthetic cannabinoids, including the following substances:<br/>
<a id="pl.8.22"></a><var>8.22</var>(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole <br/>
<a id="pl.8.23"></a><var>8.23</var>structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, <br/>
<a id="pl.8.24"></a><var>8.24</var>alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or <br/>
<a id="pl.8.25"></a><var>8.25</var>2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any <br/>
<a id="pl.8.26"></a><var>8.26</var>extent and whether or not substituted in the naphthyl ring to any extent. Examples of <br/>
<a id="pl.8.27"></a><var>8.27</var>naphthoylindoles include, but are not limited to:<br/>
<a id="pl.8.28"></a><var>8.28</var>(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);<br/>
<a id="pl.8.29"></a><var>8.29</var>(B) 1-Butul-3-(1-naphthoyl)indole (JWH-073);<br/>
<a id="pl.8.30"></a><var>8.30</var>(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);<br/>
<a id="pl.8.31"></a><var>8.31</var>(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);<br/>
<a id="pl.8.32"></a><var>8.32</var>(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);<br/>
<a id="pl.8.33"></a><var>8.33</var>(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);<br/>
<a id="pl.8.34"></a><var>8.34</var>(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);<br/>
<a id="pl.8.35"></a><var>8.35</var>(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);<br/>
<a id="pl.8.36"></a><var>8.36</var>(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);<br/>
<a id="pl.9.1"></a><var>9.1</var>(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).<br/>
<a id="pl.9.2"></a><var>9.2</var>(ii) Napthylmethylindoles, which are any compounds containing a <br/>
<a id="pl.9.3"></a><var>9.3</var>1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom <br/>
<a id="pl.9.4"></a><var>9.4</var>of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, <br/>
<a id="pl.9.5"></a><var>9.5</var>1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further <br/>
<a id="pl.9.6"></a><var>9.6</var>substituted in the indole ring to any extent and whether or not substituted in the naphthyl <br/>
<a id="pl.9.7"></a><var>9.7</var>ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:<br/>
<a id="pl.9.8"></a><var>9.8</var>(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);<br/>
<a id="pl.9.9"></a><var>9.9</var>(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184).<br/>
<a id="pl.9.10"></a><var>9.10</var>(iii) Naphthoylpyrroles, which are any compounds containing a <br/>
<a id="pl.9.11"></a><var>9.11</var>3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the <br/>
<a id="pl.9.12"></a><var>9.12</var>pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, <br/>
<a id="pl.9.13"></a><var>9.13</var>1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not <br/>
<a id="pl.9.14"></a><var>9.14</var>further substituted in the pyrrole ring to any extent, whether or not substituted in the <br/>
<a id="pl.9.15"></a><var>9.15</var>naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to, <br/>
<a id="pl.9.16"></a><var>9.16</var>(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).<br/>
<a id="pl.9.17"></a><var>9.17</var>(iv) Naphthylmethylindenes, which are any compounds containing a <br/>
<a id="pl.9.18"></a><var>9.18</var>naphthylideneindene structure with substitution at the 3-position of the indene <br/>
<a id="pl.9.19"></a><var>9.19</var>ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, <br/>
<a id="pl.9.20"></a><var>9.20</var>1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further <br/>
<a id="pl.9.21"></a><var>9.21</var>substituted in the indene ring to any extent, whether or not substituted in the naphthyl <br/>
<a id="pl.9.22"></a><var>9.22</var>ring to any extent. Examples of naphthylemethylindenes include, but are not limited to, <br/>
<a id="pl.9.23"></a><var>9.23</var>E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).<br/>
<a id="pl.9.24"></a><var>9.24</var>(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole <br/>
<a id="pl.9.25"></a><var>9.25</var>structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, <br/>
<a id="pl.9.26"></a><var>9.26</var>alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or <br/>
<a id="pl.9.27"></a><var>9.27</var>2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to <br/>
<a id="pl.9.28"></a><var>9.28</var>any extent, whether or not substituted in the phenyl ring to any extent. Examples of <br/>
<a id="pl.9.29"></a><var>9.29</var>phenylacetylindoles include, but are not limited to:<br/>
<a id="pl.9.30"></a><var>9.30</var>(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);<br/>
<a id="pl.9.31"></a><var>9.31</var>(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);<br/>
<a id="pl.9.32"></a><var>9.32</var>(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);<br/>
<a id="pl.9.33"></a><var>9.33</var>(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).<br/>
<a id="pl.9.34"></a><var>9.34</var>(vi) Cyclohexylphenols, which are compounds containing a <br/>
<a id="pl.9.35"></a><var>9.35</var>2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position <br/>
<a id="pl.9.36"></a><var>9.36</var>of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, <br/>
<a id="pl.10.1"></a><var>10.1</var>1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not <br/>
<a id="pl.10.2"></a><var>10.2</var>substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, <br/>
<a id="pl.10.3"></a><var>10.3</var>but are not limited to:<br/>
<a id="pl.10.4"></a><var>10.4</var>(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);<br/>
<a id="pl.10.5"></a><var>10.5</var>(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol <br/>
<a id="pl.10.6"></a><var>10.6</var>(Cannabicyclohexanol or CP 47,497 C8 homologue);<br/>
<a id="pl.10.7"></a><var>10.7</var>(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] <br/>
<a id="pl.10.8"></a><var>10.8</var>-phenol (CP 55,940).<br/>
<a id="pl.10.9"></a><var>10.9</var>(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole <br/>
<a id="pl.10.10"></a><var>10.10</var>structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, <br/>
<a id="pl.10.11"></a><var>10.11</var>alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or <br/>
<a id="pl.10.12"></a><var>10.12</var>2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to <br/>
<a id="pl.10.13"></a><var>10.13</var>any extent and whether or not substituted in the phenyl ring to any extent. Examples of <br/>
<a id="pl.10.14"></a><var>10.14</var>benzoylindoles include, but are not limited to:<br/>
<a id="pl.10.15"></a><var>10.15</var>(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);<br/>
<a id="pl.10.16"></a><var>10.16</var>(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);<br/>
<a id="pl.10.17"></a><var>10.17</var>(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone <br/>
<a id="pl.10.18"></a><var>10.18</var>(WIN 48,098 or Pravadoline).<br/>
<a id="pl.10.19"></a><var>10.19</var>(viii) Others specifically named:<br/>
<a id="pl.10.20"></a><var>10.20</var>(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) <br/>
<a id="pl.10.21"></a><var>10.21</var>-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);<br/>
<a id="pl.10.22"></a><var>10.22</var>(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) <br/>
<a id="pl.10.23"></a><var>10.23</var>-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);<br/>
<a id="pl.10.24"></a><var>10.24</var>(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] <br/>
<a id="pl.10.25"></a><var>10.25</var>-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2).<br/>
<a id="pl.10.26"></a><var>10.26</var>(8) (i) A controlled substance analog, to the extent that it is implicitly or explicitly <br/>
<a id="pl.10.27"></a><var>10.27</var>intended for human consumption.<br/>
<a id="pl.10.28"></a><var>10.28</var>    Subd. 3. <b>Schedule II.</b> The following items are listed in (a) Schedule II: consists of <br/>
<a id="pl.10.29"></a><var>10.29</var>the substances listed in this subdivision.<br/>
<a id="pl.10.30"></a><var>10.30</var>(1) (b) Unless specifically excepted or unless listed in another schedule, any of <br/>
<a id="pl.10.31"></a><var>10.31</var>the following substances whether produced directly or indirectly by extraction from <br/>
<a id="pl.10.32"></a><var>10.32</var>substances of vegetable origin or independently by means of chemical synthesis, or by a <br/>
<a id="pl.10.33"></a><var>10.33</var>combination of extraction and chemical synthesis:<br/>
<a id="pl.10.34"></a><var>10.34</var>(a) (1) Opium and opiate, and any salt, compound, derivative, or preparation <br/>
<a id="pl.10.35"></a><var>10.35</var>of opium or opiate, including the following: raw opium, opium extracts, opium <br/>
<a id="pl.10.36"></a><var>10.36</var>fluid extracts, powdered opium, granulated opium, tincture of opium, apomorphine, <br/>
<a id="pl.11.1"></a><var>11.1</var>codeine, ethylmorphine, hydrocodone, hydromorphone, metopon, morphine, oxycodone, <br/>
<a id="pl.11.2"></a><var>11.2</var>oxymorphone, thebaine.<br/>
<a id="pl.11.3"></a><var>11.3</var>(i) Excluding: <br/>
<a id="pl.11.4"></a><var>11.4</var>(A) apomorphine;<br/>
<a id="pl.11.5"></a><var>11.5</var>(B) thebaine-derived butorphanol;<br/>
<a id="pl.11.6"></a><var>11.6</var>(C) dextrophan;<br/>
<a id="pl.11.7"></a><var>11.7</var>(D) nalbuphine;<br/>
<a id="pl.11.8"></a><var>11.8</var>(E) nalmefene;<br/>
<a id="pl.11.9"></a><var>11.9</var>(F) naloxone;<br/>
<a id="pl.11.10"></a><var>11.10</var>(G) naltrexone;<br/>
<a id="pl.11.11"></a><var>11.11</var>(H) and their respective salts;<br/>
<a id="pl.11.12"></a><var>11.12</var>(ii) but including the following:<br/>
<a id="pl.11.13"></a><var>11.13</var>(A) opium, in all forms and extracts;<br/>
<a id="pl.11.14"></a><var>11.14</var>(B) codeine;<br/>
<a id="pl.11.15"></a><var>11.15</var>(C) dihydroetorphine;<br/>
<a id="pl.11.16"></a><var>11.16</var>(D) ethylmorphine;<br/>
<a id="pl.11.17"></a><var>11.17</var>(E) etorphine hydrochloride;<br/>
<a id="pl.11.18"></a><var>11.18</var>(F) hydrocodone;<br/>
<a id="pl.11.19"></a><var>11.19</var>(G) hydromorphone;<br/>
<a id="pl.11.20"></a><var>11.20</var>(H) metopon;<br/>
<a id="pl.11.21"></a><var>11.21</var>(I) morphine;<br/>
<a id="pl.11.22"></a><var>11.22</var>(J) oxycodone;<br/>
<a id="pl.11.23"></a><var>11.23</var>(K) oxymorphone;<br/>
<a id="pl.11.24"></a><var>11.24</var>(L) thebaine;<br/>
<a id="pl.11.25"></a><var>11.25</var>(M) oripavine;<br/>
<a id="pl.11.26"></a><var>11.26</var>(b) (2) any salt, compound, derivative, or preparation thereof which is chemically <br/>
<a id="pl.11.27"></a><var>11.27</var>equivalent or identical with any of the substances referred to in clause (a) (1), except that <br/>
<a id="pl.11.28"></a><var>11.28</var>these substances shall not include the isoquinoline alkaloids of opium.;<br/>
<a id="pl.11.29"></a><var>11.29</var>(c) (3) opium poppy and poppy straw.;<br/>
<a id="pl.11.30"></a><var>11.30</var>(d) (4) coca leaves and any salt, cocaine compound, derivative, or preparation <br/>
<a id="pl.11.31"></a><var>11.31</var>of coca leaves, including cocaine and ecgonine, the salts and isomers of cocaine and <br/>
<a id="pl.11.32"></a><var>11.32</var>ecgonine, and the salts of their isomers. (including cocaine and ecgonine and their salts, <br/>
<a id="pl.11.33"></a><var>11.33</var>isomers, derivatives, and salts of isomers and derivatives), and any salt, compound, <br/>
<a id="pl.11.34"></a><var>11.34</var>derivative, or preparation thereof which is chemically equivalent or identical with any of <br/>
<a id="pl.11.35"></a><var>11.35</var>these substances, except that the substances shall not include decocainized coca leaves or <br/>
<a id="pl.11.36"></a><var>11.36</var>extraction of coca leaves, which extractions do not contain cocaine or ecgonine;<br/>
<a id="pl.12.1"></a><var>12.1</var>(e) Any salt, compound, derivative, or preparation thereof which is chemically <br/>
<a id="pl.12.2"></a><var>12.2</var>equivalent or identical with any of the substances referred to in clause (d), except that <br/>
<a id="pl.12.3"></a><var>12.3</var>the substances shall not include decocainized coca leaves or extraction of coca leaves, <br/>
<a id="pl.12.4"></a><var>12.4</var>which extractions do not contain cocaine or ecgonine. (5) concentrate of poppy straw (the <br/>
<a id="pl.12.5"></a><var>12.5</var>crude extract of poppy straw in either liquid, solid, or powder form which contains the <br/>
<a id="pl.12.6"></a><var>12.6</var>phenanthrene alkaloids of the opium poppy).<br/>
<a id="pl.12.7"></a><var>12.7</var>(2) (c) Any of the following opiates, including their isomers, esters, ethers, salts, and <br/>
<a id="pl.12.8"></a><var>12.8</var>salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another <br/>
<a id="pl.12.9"></a><var>12.9</var>schedule, whenever the existence of such isomers, esters, ethers and salts is possible <br/>
<a id="pl.12.10"></a><var>12.10</var>within the specific chemical designation: <br/>
<a id="pl.12.11"></a><var>12.11</var>(1) alfentanil; <br/>
<a id="pl.12.12"></a><var>12.12</var>(2) alphaprodine; <br/>
<a id="pl.12.13"></a><var>12.13</var>(3) anileridine; <br/>
<a id="pl.12.14"></a><var>12.14</var>(4) bezitramide;<br/>
<a id="pl.12.15"></a><var>12.15</var>(5) bulk dextropropoxyphene (nondosage forms);<br/>
<a id="pl.12.16"></a><var>12.16</var>(6) carfentanil; <br/>
<a id="pl.12.17"></a><var>12.17</var>(7) dihydrocodeine; <br/>
<a id="pl.12.18"></a><var>12.18</var>(8) dihydromorphinone; <br/>
<a id="pl.12.19"></a><var>12.19</var>(9) diphenoxylate; <br/>
<a id="pl.12.20"></a><var>12.20</var>(10) fentanyl; <br/>
<a id="pl.12.21"></a><var>12.21</var>(11) isomethadone;<br/>
<a id="pl.12.22"></a><var>12.22</var>(12) levo-alpha-acetylmethadol (LAAM) levomethorphan; <br/>
<a id="pl.12.23"></a><var>12.23</var>(13) levorphanol; <br/>
<a id="pl.12.24"></a><var>12.24</var>(14) metazocine; <br/>
<a id="pl.12.25"></a><var>12.25</var>(15) methadone; <br/>
<a id="pl.12.26"></a><var>12.26</var>(16) methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane; <br/>
<a id="pl.12.27"></a><var>12.27</var>(17) moramide - intermediate, 2-methyl-3-morpholino-1, <br/>
<a id="pl.12.28"></a><var>12.28</var>1-diphenyl-propane-carboxylic acid; <br/>
<a id="pl.12.29"></a><var>12.29</var>(18) pethidine; <br/>
<a id="pl.12.30"></a><var>12.30</var>(19) pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine; <br/>
<a id="pl.12.31"></a><var>12.31</var>(20) pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate; <br/>
<a id="pl.12.32"></a><var>12.32</var>(21) pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid; <br/>
<a id="pl.12.33"></a><var>12.33</var>(22) phenazocine; <br/>
<a id="pl.12.34"></a><var>12.34</var>(23) piminodine; <br/>
<a id="pl.12.35"></a><var>12.35</var>(24) racemethorphan; <br/>
<a id="pl.12.36"></a><var>12.36</var>(25) racemorphan;<br/>
<a id="pl.13.1"></a><var>13.1</var>(26) remifentanil; <br/>
<a id="pl.13.2"></a><var>13.2</var>(27) sufentanil;<br/>
<a id="pl.13.3"></a><var>13.3</var>(28) tapentadol.<br/>
<a id="pl.13.4"></a><var>13.4</var>(3) (d) Unless specifically excepted or unless listed in another schedule, any <br/>
<a id="pl.13.5"></a><var>13.5</var>material, compound, mixture, or preparation which contains any quantity of the following <br/>
<a id="pl.13.6"></a><var>13.6</var>substances having a stimulant effect on the central nervous system:<br/>
<a id="pl.13.7"></a><var>13.7</var>(a) (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;<br/>
<a id="pl.13.8"></a><var>13.8</var>(b) (2) methamphetamine, its salts, isomers, and salts of its isomers;<br/>
<a id="pl.13.9"></a><var>13.9</var>(c) (3) phenmetrazine and its salts;<br/>
<a id="pl.13.10"></a><var>13.10</var>(d) (4) methylphenidate;<br/>
<a id="pl.13.11"></a><var>13.11</var>(5) lisdexamfetamine.<br/>
<a id="pl.13.12"></a><var>13.12</var>(4) (e) Unless specifically excepted or unless listed in another schedule, any <br/>
<a id="pl.13.13"></a><var>13.13</var>material, compound, mixture, or preparation which contains any quantity of the following <br/>
<a id="pl.13.14"></a><var>13.14</var>substances having a depressant effect on the central nervous system, including its salts, <br/>
<a id="pl.13.15"></a><var>13.15</var>isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of <br/>
<a id="pl.13.16"></a><var>13.16</var>isomers is possible within the specific chemical designation:<br/>
<a id="pl.13.17"></a><var>13.17</var>(a) methaqualone<br/>
<a id="pl.13.18"></a><var>13.18</var>(b) (1) amobarbital;<br/>
<a id="pl.13.19"></a><var>13.19</var>(2) glutethimide;<br/>
<a id="pl.13.20"></a><var>13.20</var>(c) (3) secobarbital;<br/>
<a id="pl.13.21"></a><var>13.21</var>(d) (4) pentobarbital;<br/>
<a id="pl.13.22"></a><var>13.22</var>(e) (5) phencyclidine;<br/>
<a id="pl.13.23"></a><var>13.23</var>(f) (6) phencyclidine immediate precursors:<br/>
<a id="pl.13.24"></a><var>13.24</var>(i) 1-phenylcyclohexylamine;<br/>
<a id="pl.13.25"></a><var>13.25</var>(ii) 1-piperidinocyclohexanecarbonitrile;<br/>
<a id="pl.13.26"></a><var>13.26</var>(7) phenylacetone.<br/>
<a id="pl.13.27"></a><var>13.27</var>(f) Hallucinogenic substances: nabilone.<br/>
<a id="pl.13.28"></a><var>13.28</var>    Subd. 4. <b>Schedule III.</b> The following items are listed in (a) Schedule III: consists of <br/>
<a id="pl.13.29"></a><var>13.29</var>the substances listed in this subdivision.<br/>
<a id="pl.13.30"></a><var>13.30</var>(1) Any material, compound, mixture, or preparation which contains any quantity of <br/>
<a id="pl.13.31"></a><var>13.31</var>Amphetamine, its salts, optical isomers, and salts of its optical isomers; Phenmetrazine <br/>
<a id="pl.13.32"></a><var>13.32</var>and its salts; Methamphetamine, its salts, isomers, and salts of isomers; Methylphenidate; <br/>
<a id="pl.13.33"></a><var>13.33</var>and which is required by federal law to be labeled with the symbol prescribed by 21 Code <br/>
<a id="pl.13.34"></a><var>13.34</var>of Federal Regulations Section 1302.03 and in effect on February 1, 1976 designating that <br/>
<a id="pl.13.35"></a><var>13.35</var>the drug is listed as a Schedule III controlled substance under federal law. (b) Stimulants. <br/>
<a id="pl.13.36"></a><var>13.36</var>Unless specifically excepted or unless listed in another schedule, any material, compound, <br/>
<a id="pl.14.1"></a><var>14.1</var>mixture, or preparation which contains any quantity of the following substances having <br/>
<a id="pl.14.2"></a><var>14.2</var>a potential for abuse associated with a stimulant effect on the central nervous system, <br/>
<a id="pl.14.3"></a><var>14.3</var>including its salts, isomers, and salts of such isomers whenever the existence of such salts, <br/>
<a id="pl.14.4"></a><var>14.4</var>isomers, and salts of isomers is possible within the specific chemical designation: <br/>
<a id="pl.14.5"></a><var>14.5</var>(1) benzphetamine; <br/>
<a id="pl.14.6"></a><var>14.6</var>(2) chlorphentermine; <br/>
<a id="pl.14.7"></a><var>14.7</var>(3) clortermine; <br/>
<a id="pl.14.8"></a><var>14.8</var>(4) phendimetrazine.<br/>
<a id="pl.14.9"></a><var>14.9</var>(2) (c) Depressants. Unless specifically excepted or unless listed in another schedule, <br/>
<a id="pl.14.10"></a><var>14.10</var>any material, compound, mixture, or preparation which contains any quantity of the <br/>
<a id="pl.14.11"></a><var>14.11</var>following substances having a potential for abuse associated with a depressant effect on <br/>
<a id="pl.14.12"></a><var>14.12</var>the central nervous system:<br/>
<a id="pl.14.13"></a><var>14.13</var>(a) (1) any compound, mixture, or preparation containing amobarbital, secobarbital, <br/>
<a id="pl.14.14"></a><var>14.14</var>pentobarbital or any salt thereof and one or more other active medicinal ingredients which <br/>
<a id="pl.14.15"></a><var>14.15</var>are not listed in any schedule.;<br/>
<a id="pl.14.16"></a><var>14.16</var>(b) (2) any suppository dosage form containing amobarbital, secobarbital, <br/>
<a id="pl.14.17"></a><var>14.17</var>pentobarbital, or any salt of any of these drugs and approved by the food and drug <br/>
<a id="pl.14.18"></a><var>14.18</var>administration for marketing only as a suppository.;<br/>
<a id="pl.14.19"></a><var>14.19</var>(c) (3) any substance which contains any quantity of a derivative of barbituric acid, <br/>
<a id="pl.14.20"></a><var>14.20</var>or any salt of a derivative of barbituric acid, except those substances which are specifically <br/>
<a id="pl.14.21"></a><var>14.21</var>listed in other schedules: Chlorhexadol; Glutethimide; Lysergic acid; Lysergic acid amide; <br/>
<a id="pl.14.22"></a><var>14.22</var>Methyprylon; Sulfondiethylmethane; Sulfonethylmethane; Sulfonmethane.;<br/>
<a id="pl.14.23"></a><var>14.23</var>(d) Gamma hydroxybutyrate, any salt, compound, derivative, or preparation of <br/>
<a id="pl.14.24"></a><var>14.24</var>gamma hydroxybutyrate, including any isomers, esters, and ethers and salts of isomers, <br/>
<a id="pl.14.25"></a><var>14.25</var>esters, and ethers of gamma hydroxybutyrate whenever the existence of such isomers, <br/>
<a id="pl.14.26"></a><var>14.26</var>esters, and salts is possible within the specific chemical designation. (4) any drug product <br/>
<a id="pl.14.27"></a><var>14.27</var>containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, <br/>
<a id="pl.14.28"></a><var>14.28</var>for which an application is approved under section 505 of the federal Food, Drug, and <br/>
<a id="pl.14.29"></a><var>14.29</var>Cosmetic Act;<br/>
<a id="pl.14.30"></a><var>14.30</var>(5) any of the following substances: <br/>
<a id="pl.14.31"></a><var>14.31</var>(i) chlorhexadol;<br/>
<a id="pl.14.32"></a><var>14.32</var>(ii) ketamine, its salts, isomers and salts of isomers;<br/>
<a id="pl.14.33"></a><var>14.33</var>(iii) lysergic acid;<br/>
<a id="pl.14.34"></a><var>14.34</var>(iv) lysergic acid amide;<br/>
<a id="pl.14.35"></a><var>14.35</var>(v) methyprylon;<br/>
<a id="pl.14.36"></a><var>14.36</var>(vi) sulfondiethylmethane;<br/>
<a id="pl.15.1"></a><var>15.1</var>(vii) sulfonenthylmethane;<br/>
<a id="pl.15.2"></a><var>15.2</var>(viii) sulfonmethane;<br/>
<a id="pl.15.3"></a><var>15.3</var>(ix) tiletamine and zolazepam and any salt thereof;<br/>
<a id="pl.15.4"></a><var>15.4</var>(x) embutramide.<br/>
<a id="pl.15.5"></a><var>15.5</var>(3) Any material, compound, mixture, or preparation which contains any quantity of <br/>
<a id="pl.15.6"></a><var>15.6</var>the following substances having a potential for abuse associated with a stimulant effect on <br/>
<a id="pl.15.7"></a><var>15.7</var>the central nervous system:<br/>
<a id="pl.15.8"></a><var>15.8</var>(a) Benzphetamine<br/>
<a id="pl.15.9"></a><var>15.9</var>(b) Chlorphentermine<br/>
<a id="pl.15.10"></a><var>15.10</var>(c) Clortermine<br/>
<a id="pl.15.11"></a><var>15.11</var>(d) Mazindol<br/>
<a id="pl.15.12"></a><var>15.12</var>(e) Phendimetrazine.<br/>
<a id="pl.15.13"></a><var>15.13</var>(4) (d) Nalorphine.<br/>
<a id="pl.15.14"></a><var>15.14</var>(5) Any material, compound, mixture, or preparation containing limited quantities <br/>
<a id="pl.15.15"></a><var>15.15</var>of any of the following narcotic drugs, or any salts thereof (e) Narcotic drugs. Unless <br/>
<a id="pl.15.16"></a><var>15.16</var>specifically excepted or unless listed in another schedule, any material, compound, <br/>
<a id="pl.15.17"></a><var>15.17</var>mixture, or preparation containing any of the following narcotic drugs, or their salts <br/>
<a id="pl.15.18"></a><var>15.18</var>calculated as the free anhydrous base or alkaloid, in limited quantities as follows:<br/>
<a id="pl.15.19"></a><var>15.19</var>(a) (1) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 <br/>
<a id="pl.15.20"></a><var>15.20</var>milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid <br/>
<a id="pl.15.21"></a><var>15.21</var>of opium.;<br/>
<a id="pl.15.22"></a><var>15.22</var>(b) (2) not more than 1.80 grams of codeine per 100 milliliters or not more than 90 <br/>
<a id="pl.15.23"></a><var>15.23</var>milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized <br/>
<a id="pl.15.24"></a><var>15.24</var>therapeutic amounts.;<br/>
<a id="pl.15.25"></a><var>15.25</var>(c) (3) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or <br/>
<a id="pl.15.26"></a><var>15.26</var>not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an <br/>
<a id="pl.15.27"></a><var>15.27</var>isoquinoline alkaloid of opium.;<br/>
<a id="pl.15.28"></a><var>15.28</var>(d) (4) not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not <br/>
<a id="pl.15.29"></a><var>15.29</var>more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients <br/>
<a id="pl.15.30"></a><var>15.30</var>in recognized therapeutic amounts.;<br/>
<a id="pl.15.31"></a><var>15.31</var>(e) (5) not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more <br/>
<a id="pl.15.32"></a><var>15.32</var>than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in <br/>
<a id="pl.15.33"></a><var>15.33</var>recognized therapeutic amounts.;<br/>
<a id="pl.15.34"></a><var>15.34</var>(f) (6) not more than 300 milligrams of ethylmorphine per 100 milliliters or not more <br/>
<a id="pl.15.35"></a><var>15.35</var>than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in <br/>
<a id="pl.15.36"></a><var>15.36</var>recognized therapeutic amounts.;<br/>
<a id="pl.16.1"></a><var>16.1</var>(g) (7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, <br/>
<a id="pl.16.2"></a><var>16.2</var>or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic <br/>
<a id="pl.16.3"></a><var>16.3</var>ingredients in recognized therapeutic amounts.;<br/>
<a id="pl.16.4"></a><var>16.4</var>(h) (8) not more than 50 milligrams of morphine per 100 milliliters or per 100 grams <br/>
<a id="pl.16.5"></a><var>16.5</var>with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.;<br/>
<a id="pl.16.6"></a><var>16.6</var>(6) (f)  Anabolic steroids, which and human growth hormone.<br/>
<a id="pl.16.7"></a><var>16.7</var>(1) Anabolic steroids, for purposes of this subdivision, means any drug or <br/>
<a id="pl.16.8"></a><var>16.8</var>hormonal substance, chemically and pharmacologically related to testosterone, other <br/>
<a id="pl.16.9"></a><var>16.9</var>than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes: <br/>
<a id="pl.16.10"></a><var>16.10</var>androstanediol; androstanedione; androstenediol; androstenedione; bolasterone; <br/>
<a id="pl.16.11"></a><var>16.11</var>boldenone; calusterone; chlorotestosterone; chorionic gonadotropin; clostebol; <br/>
<a id="pl.16.12"></a><var>16.12</var>dehydrochloromethyltestosterone; (triangle)1-dihydrotestosterone; 4-dihydrotestosterone; <br/>
<a id="pl.16.13"></a><var>16.13</var>drostanolone; ethylestrenol; fluoxymesterone; formebolone; furazabol; human <br/>
<a id="pl.16.14"></a><var>16.14</var>growth hormones; 13b-ethyl-17a-hydroxygon-4-en-3-one; 4-hydroxytestosterone; <br/>
<a id="pl.16.15"></a><var>16.15</var>4-hydroxy-19-nortestosterone; mestanolone; mesterolone; methandienone; <br/>
<a id="pl.16.16"></a><var>16.16</var>methandranone; methandriol; methandrostenolone; methenolone; 17a-methyl-3b, <br/>
<a id="pl.16.17"></a><var>16.17</var>17b-dihydroxy-5a-androstane; 17a-methyl-3a, 17b-dihydroxy-5a-androstane; <br/>
<a id="pl.16.18"></a><var>16.18</var>17a-methyl-3b, 17b-dihydroxyandrost-4-ene; 17a-methyl-4-hydroxynandrolone; <br/>
<a id="pl.16.19"></a><var>16.19</var>methyldienolone; methyltrienolone; methyltestosterone; mibolerone; <br/>
<a id="pl.16.20"></a><var>16.20</var>17a-methyl-(triangle)1-dihydrotestosterone; nandrolone; nandrolone phenpropionate; <br/>
<a id="pl.16.21"></a><var>16.21</var>norandrostenediol; norandrostenedione; norbolethone; norclostebol; norethandrolone; <br/>
<a id="pl.16.22"></a><var>16.22</var>normethandrolone; oxandrolone; oxymesterone; oxymetholone; stanolone; stanozolol; <br/>
<a id="pl.16.23"></a><var>16.23</var>stenbolone; testolactone; testosterone; testosterone propionate; tetrahydrogestrinone; <br/>
<a id="pl.16.24"></a><var>16.24</var>trenbolone; and any salt, ester, or ether of a drug or substance described in this paragraph.<br/>
<a id="pl.16.25"></a><var>16.25</var>(i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane;<br/>
<a id="pl.16.26"></a><var>16.26</var>(ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;<br/>
<a id="pl.16.27"></a><var>16.27</var>(iii) androstanedione (5[alpha]-androstan-3,17-dione);<br/>
<a id="pl.16.28"></a><var>16.28</var>(iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene;<br/>
<a id="pl.16.29"></a><var>16.29</var>(v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);<br/>
<a id="pl.16.30"></a><var>16.30</var>(vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);<br/>
<a id="pl.16.31"></a><var>16.31</var>(vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);<br/>
<a id="pl.16.32"></a><var>16.32</var>(viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione);<br/>
<a id="pl.16.33"></a><var>16.33</var>(ix) 4-androstenedione (androst-4-en-3,17-dione);<br/>
<a id="pl.16.34"></a><var>16.34</var>(x) 5-androstenedione (androst-5-en-3,17-dione);<br/>
<a id="pl.16.35"></a><var>16.35</var>(xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);<br/>
<a id="pl.16.36"></a><var>16.36</var>(xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one);<br/>
<a id="pl.17.1"></a><var>17.1</var>(xiii) boldione (androsta-1,4-diene-3,17-dione);<br/>
<a id="pl.17.2"></a><var>17.2</var>(xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one);<br/>
<a id="pl.17.3"></a><var>17.3</var>(xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one);<br/>
<a id="pl.17.4"></a><var>17.4</var>(xvi) dehydrochloromethyltestosterone <br/>
<a id="pl.17.5"></a><var>17.5</var>(4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one);<br/>
<a id="pl.17.6"></a><var>17.6</var>(xvii) desoxymethyltestosterone <br/>
<a id="pl.17.7"></a><var>17.7</var>(17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol);<br/>
<a id="pl.17.8"></a><var>17.8</var>(xviii) [delta]1-dihydrotestosterone- <br/>
<a id="pl.17.9"></a><var>17.9</var>(17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);<br/>
<a id="pl.17.10"></a><var>17.10</var>(xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one);<br/>
<a id="pl.17.11"></a><var>17.11</var>(xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one);<br/>
<a id="pl.17.12"></a><var>17.12</var>(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene);<br/>
<a id="pl.17.13"></a><var>17.13</var>(xxii) fluoxymesterone <br/>
<a id="pl.17.14"></a><var>17.14</var>(9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one);<br/>
<a id="pl.17.15"></a><var>17.15</var>(xxiii) formebolone <br/>
<a id="pl.17.16"></a><var>17.16</var>(2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one);<br/>
<a id="pl.17.17"></a><var>17.17</var>(xxiv) furazabol <br/>
<a id="pl.17.18"></a><var>17.18</var>(17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta] <br/>
<a id="pl.17.19"></a><var>17.19</var>-hydroxygon-4-en-3-one;<br/>
<a id="pl.17.20"></a><var>17.20</var>(xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one);<br/>
<a id="pl.17.21"></a><var>17.21</var>(xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one);<br/>
<a id="pl.17.22"></a><var>17.22</var>(xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);<br/>
<a id="pl.17.23"></a><var>17.23</var>(xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one);<br/>
<a id="pl.17.24"></a><var>17.24</var>(xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one);<br/>
<a id="pl.17.25"></a><var>17.25</var>(xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene);<br/>
<a id="pl.17.26"></a><var>17.26</var>(xxxi) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one);<br/>
<a id="pl.17.27"></a><var>17.27</var>(xxxii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane;<br/>
<a id="pl.17.28"></a><var>17.28</var>(xxxiii) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane;<br/>
<a id="pl.17.29"></a><var>17.29</var>(xxxiv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;<br/>
<a id="pl.17.30"></a><var>17.30</var>(xxxv) 17[alpha]-methyl-4-hydroxynandrolone <br/>
<a id="pl.17.31"></a><var>17.31</var>(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);<br/>
<a id="pl.17.32"></a><var>17.32</var>(xxxvi) methyldienolone <br/>
<a id="pl.17.33"></a><var>17.33</var>(17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);<br/>
<a id="pl.17.34"></a><var>17.34</var>(xxxvii) methyltrienolone <br/>
<a id="pl.17.35"></a><var>17.35</var>(17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);<br/>
<a id="pl.18.1"></a><var>18.1</var>(xxxviii) methyltestosterone <br/>
<a id="pl.18.2"></a><var>18.2</var>(17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one);<br/>
<a id="pl.18.3"></a><var>18.3</var>(xxxix) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one);<br/>
<a id="pl.18.4"></a><var>18.4</var>(xl) 17[alpha]-methyl-[delta]1-dihydrotestosterone <br/>
<a id="pl.18.5"></a><var>18.5</var>(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one);<br/>
<a id="pl.18.6"></a><var>18.6</var>(xli) nandrolone (17[beta]-hydroxyestr-4-en-3-one);<br/>
<a id="pl.18.7"></a><var>18.7</var>(xlii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene;<br/>
<a id="pl.18.8"></a><var>18.8</var>(xliii) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol <br/>
<a id="pl.18.9"></a><var>18.9</var>(3[beta],17[beta]-dihydroxyestr-5-ene;<br/>
<a id="pl.18.10"></a><var>18.10</var>(xliv) 3[alpha],17[beta]-dihydroxyestr-5-ene);<br/>
<a id="pl.18.11"></a><var>18.11</var>(xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);<br/>
<a id="pl.18.12"></a><var>18.12</var>(xlvi) 19-nor-5-androstenedione (estr-5-en-3,17-dione);<br/>
<a id="pl.18.13"></a><var>18.13</var>(xlvii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one);<br/>
<a id="pl.18.14"></a><var>18.14</var>(xlviii) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);<br/>
<a id="pl.18.15"></a><var>18.15</var>(xlix) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one);<br/>
<a id="pl.18.16"></a><var>18.16</var>(l) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);<br/>
<a id="pl.18.17"></a><var>18.17</var>(li) oxandrolone <br/>
<a id="pl.18.18"></a><var>18.18</var>(17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one);<br/>
<a id="pl.18.19"></a><var>18.19</var>(lii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one);<br/>
<a id="pl.18.20"></a><var>18.20</var>(liii) oxymetholone <br/>
<a id="pl.18.21"></a><var>18.21</var>(17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one);<br/>
<a id="pl.18.22"></a><var>18.22</var>(liv) stanozolol <br/>
<a id="pl.18.23"></a><var>18.23</var>(17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole);<br/>
<a id="pl.18.24"></a><var>18.24</var>(lv) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one);<br/>
<a id="pl.18.25"></a><var>18.25</var>(lvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid <br/>
<a id="pl.18.26"></a><var>18.26</var>lactone);<br/>
<a id="pl.18.27"></a><var>18.27</var>(lvii) testosterone (17[beta]-hydroxyandrost-4-en-3-one);<br/>
<a id="pl.18.28"></a><var>18.28</var>(lviii) tetrahydrogestrinone <br/>
<a id="pl.18.29"></a><var>18.29</var>(13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one);<br/>
<a id="pl.18.30"></a><var>18.30</var>(lix) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one);<br/>
<a id="pl.18.31"></a><var>18.31</var>(lx) any salt, ester, or ether of a drug or substance described in this paragraph. <br/>
<a id="pl.18.32"></a><var>18.32</var>Anabolic steroids are not included if they are: (i) (A) expressly intended for administration <br/>
<a id="pl.18.33"></a><var>18.33</var>through implants to cattle or other nonhuman species; and (ii) (B) approved by the United <br/>
<a id="pl.18.34"></a><var>18.34</var>States Food and Drug Administration for that use.;<br/>
<a id="pl.18.35"></a><var>18.35</var>(2) Human growth hormones.<br/>
<a id="pl.19.1"></a><var>19.1</var>(g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and <br/>
<a id="pl.19.2"></a><var>19.2</var>encapsulated in a soft gelatin capsule in a United States Food and Drug Administration <br/>
<a id="pl.19.3"></a><var>19.3</var>approved product.<br/>
<a id="pl.19.4"></a><var>19.4</var>(h) Any material, compound, mixture, or preparation containing the following <br/>
<a id="pl.19.5"></a><var>19.5</var>narcotic drug or its salt: buprenorphine.<br/>
<a id="pl.19.6"></a><var>19.6</var>    Subd. 5. <b>Schedule IV.</b> The following items are listed in Schedule IV: Barbital; <br/>
<a id="pl.19.7"></a><var>19.7</var>Butorphanol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clonazepam; <br/>
<a id="pl.19.8"></a><var>19.8</var>Clorazepate; Diazepam; Diethylpropion; Ethchlorvynol; Ethinamate; Fenfluramine; <br/>
<a id="pl.19.9"></a><var>19.9</var>Flurazepam; Mebutamate; Methohexital; Meprobamate except when in combination with <br/>
<a id="pl.19.10"></a><var>19.10</var>the following drugs in the following or lower concentrations: conjugated estrogens, 0.4 <br/>
<a id="pl.19.11"></a><var>19.11</var>mg; tridihexethyl chloride, 25mg; pentaerythritol tetranitrate, 20 mg; Methylphenobarbital; <br/>
<a id="pl.19.12"></a><var>19.12</var>Oxazepam; Paraldehyde; Pemoline; Petrichloral; Phenobarbital; and Phentermine (a) <br/>
<a id="pl.19.13"></a><var>19.13</var>Schedule IV consists of the substances listed in this subdivision.<br/>
<a id="pl.19.14"></a><var>19.14</var>(b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, <br/>
<a id="pl.19.15"></a><var>19.15</var>any material, compound, mixture, or preparation containing any of the following narcotic <br/>
<a id="pl.19.16"></a><var>19.16</var>drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities <br/>
<a id="pl.19.17"></a><var>19.17</var>as follows:<br/>
<a id="pl.19.18"></a><var>19.18</var>(1) not more than one milligram of difenoxin and not less than 25 micrograms of <br/>
<a id="pl.19.19"></a><var>19.19</var>atropine sulfate per dosage unit;<br/>
<a id="pl.19.20"></a><var>19.20</var>(2) dextropropoxyphene (Darvon and Darvocet).<br/>
<a id="pl.19.21"></a><var>19.21</var>(c) Depressants. Unless specifically excepted or unless listed in another schedule, <br/>
<a id="pl.19.22"></a><var>19.22</var>any material, compound, mixture, or preparation containing any quantity of the following <br/>
<a id="pl.19.23"></a><var>19.23</var>substances, including its salts, isomers, and salts of isomers whenever the existence of the <br/>
<a id="pl.19.24"></a><var>19.24</var>salts, isomers, and salts of isomers is possible: <br/>
<a id="pl.19.25"></a><var>19.25</var>(1) alprazolam;<br/>
<a id="pl.19.26"></a><var>19.26</var>(2) barbital;<br/>
<a id="pl.19.27"></a><var>19.27</var>(3) bromazepam;<br/>
<a id="pl.19.28"></a><var>19.28</var>(4) camazepam;<br/>
<a id="pl.19.29"></a><var>19.29</var>(5) carisoprodol;<br/>
<a id="pl.19.30"></a><var>19.30</var>(6) chloral betaine;<br/>
<a id="pl.19.31"></a><var>19.31</var>(7) chloral hydrate;<br/>
<a id="pl.19.32"></a><var>19.32</var>(8) chlordiazepoxide;<br/>
<a id="pl.19.33"></a><var>19.33</var>(9) clobazam;<br/>
<a id="pl.19.34"></a><var>19.34</var>(10) clonazepam;<br/>
<a id="pl.19.35"></a><var>19.35</var>(11) clorazepate;<br/>
<a id="pl.19.36"></a><var>19.36</var>(12) clotiazepam;<br/>
<a id="pl.20.1"></a><var>20.1</var>(13) cloxazolam;<br/>
<a id="pl.20.2"></a><var>20.2</var>(14) delorazepam;<br/>
<a id="pl.20.3"></a><var>20.3</var>(15) diazepam;<br/>
<a id="pl.20.4"></a><var>20.4</var>(16) dichloralphenazone;<br/>
<a id="pl.20.5"></a><var>20.5</var>(17) estazolam;<br/>
<a id="pl.20.6"></a><var>20.6</var>(18) ethchlorvynol;<br/>
<a id="pl.20.7"></a><var>20.7</var>(19) ethinamate;<br/>
<a id="pl.20.8"></a><var>20.8</var>(20) ethyl loflazepate;<br/>
<a id="pl.20.9"></a><var>20.9</var>(21) fludiazepam;<br/>
<a id="pl.20.10"></a><var>20.10</var>(22) flurazepam;<br/>
<a id="pl.20.11"></a><var>20.11</var>(23) halazepam;<br/>
<a id="pl.20.12"></a><var>20.12</var>(24) haloxazolam;<br/>
<a id="pl.20.13"></a><var>20.13</var>(25) ketazolam;<br/>
<a id="pl.20.14"></a><var>20.14</var>(26) loprazolam;<br/>
<a id="pl.20.15"></a><var>20.15</var>(27) lorazepam;<br/>
<a id="pl.20.16"></a><var>20.16</var>(28) lormetazepam mebutamate;<br/>
<a id="pl.20.17"></a><var>20.17</var>(29) medazepam;<br/>
<a id="pl.20.18"></a><var>20.18</var>(30) meprobamate;<br/>
<a id="pl.20.19"></a><var>20.19</var>(31) methohexital;<br/>
<a id="pl.20.20"></a><var>20.20</var>(32) methylphenobarbital;<br/>
<a id="pl.20.21"></a><var>20.21</var>(33) midazolam;<br/>
<a id="pl.20.22"></a><var>20.22</var>(34) nimetazepam;<br/>
<a id="pl.20.23"></a><var>20.23</var>(35) nitrazepamnordiazepam;<br/>
<a id="pl.20.24"></a><var>20.24</var>(36) oxazepam;<br/>
<a id="pl.20.25"></a><var>20.25</var>(37) oxazolam;<br/>
<a id="pl.20.26"></a><var>20.26</var>(38) paraldehydepetrichloral;<br/>
<a id="pl.20.27"></a><var>20.27</var>(39) phenobarbital;<br/>
<a id="pl.20.28"></a><var>20.28</var>(40) pinazepam;<br/>
<a id="pl.20.29"></a><var>20.29</var>(41) prazepam;<br/>
<a id="pl.20.30"></a><var>20.30</var>(42) quazepam;<br/>
<a id="pl.20.31"></a><var>20.31</var>(43) temazepam;<br/>
<a id="pl.20.32"></a><var>20.32</var>(44) tetrazepam;<br/>
<a id="pl.20.33"></a><var>20.33</var>(45) triazolam;<br/>
<a id="pl.20.34"></a><var>20.34</var>(46) zaleplon;<br/>
<a id="pl.20.35"></a><var>20.35</var>(47) zolpidem;<br/>
<a id="pl.20.36"></a><var>20.36</var>(48) zopiclone.<br/>
<a id="pl.21.1"></a><var>21.1</var>(d) Any material, compound, mixture, or preparation which contains any quantity of <br/>
<a id="pl.21.2"></a><var>21.2</var>the following substance including its salts, isomers, and salts of such isomers, whenever <br/>
<a id="pl.21.3"></a><var>21.3</var>the existence of such salts, isomers, and salts of isomers is possible: fenfluramine.<br/>
<a id="pl.21.4"></a><var>21.4</var>(e) Stimulants. Unless specifically excepted or unless listed in another schedule, <br/>
<a id="pl.21.5"></a><var>21.5</var>any material, compound, mixture, or preparation which contains any quantity of the <br/>
<a id="pl.21.6"></a><var>21.6</var>following substances having a stimulant effect on the central nervous system, including its <br/>
<a id="pl.21.7"></a><var>21.7</var>salts, isomers, and salts of isomers:<br/>
<a id="pl.21.8"></a><var>21.8</var>(1) cathine (norpseudoephedrine);<br/>
<a id="pl.21.9"></a><var>21.9</var>(2) diethylpropion;<br/>
<a id="pl.21.10"></a><var>21.10</var>(3) fencamfamine;<br/>
<a id="pl.21.11"></a><var>21.11</var>(4) fenproporex;<br/>
<a id="pl.21.12"></a><var>21.12</var>(5) mazindol;<br/>
<a id="pl.21.13"></a><var>21.13</var>(6) mefenorex;<br/>
<a id="pl.21.14"></a><var>21.14</var>(7) modafinil;<br/>
<a id="pl.21.15"></a><var>21.15</var>(8) pemoline (including organometallic complexes and chelates thereof);<br/>
<a id="pl.21.16"></a><var>21.16</var>(9) phentermine;<br/>
<a id="pl.21.17"></a><var>21.17</var>(10) pipradol;<br/>
<a id="pl.21.18"></a><var>21.18</var>(11) sibutramine;<br/>
<a id="pl.21.19"></a><var>21.19</var>(12) SPA (1-dimethylamino-1,2-diphenylethane).<br/>
<a id="pl.21.20"></a><var>21.20</var>    Subd. 6. <b>Schedule V; restrictions on methamphetamine precursor drugs.</b> (a) As <br/>
<a id="pl.21.21"></a><var>21.21</var>used in this subdivision, the following terms have the meanings given:<br/>
<a id="pl.21.22"></a><var>21.22</var>(1) "methamphetamine precursor drug" means any compound, mixture, or <br/>
<a id="pl.21.23"></a><var>21.23</var>preparation intended for human consumption containing ephedrine or pseudoephedrine as <br/>
<a id="pl.21.24"></a><var>21.24</var>its sole active ingredient or as one of its active ingredients; and<br/>
<a id="pl.21.25"></a><var>21.25</var>(2) "over-the-counter sale" means a retail sale of a drug or product but does not <br/>
<a id="pl.21.26"></a><var>21.26</var>include the sale of a drug or product pursuant to the terms of a valid prescription.<br/>
<a id="pl.21.27"></a><var>21.27</var>(b) The following items are listed in Schedule V:<br/>
<a id="pl.21.28"></a><var>21.28</var>(1) any compound, mixture, or preparation containing any of the following limited <br/>
<a id="pl.21.29"></a><var>21.29</var>quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal <br/>
<a id="pl.21.30"></a><var>21.30</var>ingredients in sufficient proportion to confer upon the compound, mixture or preparation <br/>
<a id="pl.21.31"></a><var>21.31</var>valuable medicinal qualities other than those possessed by the narcotic drug alone:<br/>
<a id="pl.21.32"></a><var>21.32</var>(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 <br/>
<a id="pl.21.33"></a><var>21.33</var>grams;<br/>
<a id="pl.21.34"></a><var>21.34</var>(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 <br/>
<a id="pl.21.35"></a><var>21.35</var>grams;<br/>
<a id="pl.22.1"></a><var>22.1</var>(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms <br/>
<a id="pl.22.2"></a><var>22.2</var>of atropine sulfate per dosage unit; or<br/>
<a id="pl.22.3"></a><var>22.3</var>(iv) not more than 15 milligrams of anhydrous morphine per 100 milliliters or per <br/>
<a id="pl.22.4"></a><var>22.4</var>100 grams; and 100 milligrams of opium per 100 milliliters or per 100 grams; or<br/>
<a id="pl.22.5"></a><var>22.5</var>(v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of <br/>
<a id="pl.22.6"></a><var>22.6</var>atropine sulfate per dosage unit.<br/>
<a id="pl.22.7"></a><var>22.7</var>(2) Stimulants. Unless specifically exempted or excluded or unless listed in another <br/>
<a id="pl.22.8"></a><var>22.8</var>schedule, any material, compound, mixture, or preparation that contains any quantity of <br/>
<a id="pl.22.9"></a><var>22.9</var>the following substance having a stimulant effect on the central nervous system, including <br/>
<a id="pl.22.10"></a><var>22.10</var>its salts, isomers, and salts of isomers: pyrovalerone.<br/>
<a id="pl.22.11"></a><var>22.11</var>(3) Depressants. Unless specifically exempted or excluded or unless listed in another <br/>
<a id="pl.22.12"></a><var>22.12</var>schedule, any material, compound, mixture, or preparation that contains any quantity <br/>
<a id="pl.22.13"></a><var>22.13</var>of the following substance having a depressant effect on the central nervous system, <br/>
<a id="pl.22.14"></a><var>22.14</var>including its salts, isomers, and salts of isomers:<br/>
<a id="pl.22.15"></a><var>22.15</var>(i) pregabalin;<br/>
<a id="pl.22.16"></a><var>22.16</var>(ii) lacosamide.<br/>
<a id="pl.22.17"></a><var>22.17</var>(2) (4) Any compound, mixture, or preparation containing ephedrine or <br/>
<a id="pl.22.18"></a><var>22.18</var>pseudoephedrine as its sole active ingredient or as one of its active ingredients.<br/>
<a id="pl.22.19"></a><var>22.19</var>(c) No person may sell in a single over-the-counter sale more than two packages <br/>
<a id="pl.22.20"></a><var>22.20</var>of a methamphetamine precursor drug or a combination of methamphetamine precursor <br/>
<a id="pl.22.21"></a><var>22.21</var>drugs or any combination of packages exceeding a total weight of six grams, calculated as <br/>
<a id="pl.22.22"></a><var>22.22</var>the base.<br/>
<a id="pl.22.23"></a><var>22.23</var>(d) Over-the-counter sales of methamphetamine precursor drugs are limited to:<br/>
<a id="pl.22.24"></a><var>22.24</var>(1) packages containing not more than a total of three grams of one or <br/>
<a id="pl.22.25"></a><var>22.25</var>more methamphetamine precursor drugs, calculated in terms of ephedrine base or <br/>
<a id="pl.22.26"></a><var>22.26</var>pseudoephedrine base; or<br/>
<a id="pl.22.27"></a><var>22.27</var>(2) for nonliquid products, sales in blister packs, where each blister contains not <br/>
<a id="pl.22.28"></a><var>22.28</var>more than two dosage units, or, if the use of blister packs is not technically feasible, sales <br/>
<a id="pl.22.29"></a><var>22.29</var>in unit dose packets or pouches.<br/>
<a id="pl.22.30"></a><var>22.30</var>(e) A business establishment that offers for sale methamphetamine precursor drugs <br/>
<a id="pl.22.31"></a><var>22.31</var>in an over-the-counter sale shall ensure that all packages of the drugs are displayed <br/>
<a id="pl.22.32"></a><var>22.32</var>behind a checkout counter where the public is not permitted and are offered for sale only <br/>
<a id="pl.22.33"></a><var>22.33</var>by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The <br/>
<a id="pl.22.34"></a><var>22.34</var>establishment shall ensure that the person making the sale requires the buyer:<br/>
<a id="pl.22.35"></a><var>22.35</var>(1) to provide photographic identification showing the buyer's date of birth; and<br/>
<a id="pl.23.1"></a><var>23.1</var>(2) to sign a written or electronic document detailing the date of the sale, the name <br/>
<a id="pl.23.2"></a><var>23.2</var>of the buyer, and the amount of the drug sold.<br/>
<a id="pl.23.3"></a><var>23.3</var>A document described under clause (2) must be retained by the establishment for <br/>
<a id="pl.23.4"></a><var>23.4</var>at least three years and must at all reasonable times be open to the inspection of any <br/>
<a id="pl.23.5"></a><var>23.5</var>law enforcement agency.<br/>
<a id="pl.23.6"></a><var>23.6</var>Nothing in this paragraph requires the buyer to obtain a prescription for the drug's <br/>
<a id="pl.23.7"></a><var>23.7</var>purchase.<br/>
<a id="pl.23.8"></a><var>23.8</var>(f) No person may acquire through over-the-counter sales more than six grams of <br/>
<a id="pl.23.9"></a><var>23.9</var>methamphetamine precursor drugs, calculated as the base, within a 30-day period.<br/>
<a id="pl.23.10"></a><var>23.10</var>(g) No person may sell in an over-the-counter sale a methamphetamine precursor <br/>
<a id="pl.23.11"></a><var>23.11</var>drug to a person under the age of 18 years. It is an affirmative defense to a charge under <br/>
<a id="pl.23.12"></a><var>23.12</var>this paragraph if the defendant proves by a preponderance of the evidence that the <br/>
<a id="pl.23.13"></a><var>23.13</var>defendant reasonably and in good faith relied on proof of age as described in section <br/>
<statute_ref><a id="pl.23.14"></a><var>23.14</var>340A.503, subdivision 6
         </statute_ref>.<br/>
<a id="pl.23.15"></a><var>23.15</var>(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of <br/>
<a id="pl.23.16"></a><var>23.16</var>a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to <br/>
<a id="pl.23.17"></a><var>23.17</var>payment of a fine of not more than $1,000, or both.<br/>
<a id="pl.23.18"></a><var>23.18</var>(i) An owner, operator, supervisor, or manager of a business establishment that <br/>
<a id="pl.23.19"></a><var>23.19</var>offers for sale methamphetamine precursor drugs whose employee or agent is convicted of <br/>
<a id="pl.23.20"></a><var>23.20</var>or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal <br/>
<a id="pl.23.21"></a><var>23.21</var>penalties for violating any of those paragraphs if the person:<br/>
<a id="pl.23.22"></a><var>23.22</var>(1) did not have prior knowledge of, participate in, or direct the employee or agent to <br/>
<a id="pl.23.23"></a><var>23.23</var>commit the violation; and<br/>
<a id="pl.23.24"></a><var>23.24</var>(2) documents that an employee training program was in place to provide the <br/>
<a id="pl.23.25"></a><var>23.25</var>employee or agent with information on the state and federal laws and regulations regarding <br/>
<a id="pl.23.26"></a><var>23.26</var>methamphetamine precursor drugs.<br/>
<a id="pl.23.27"></a><var>23.27</var>(j) Any person employed by a business establishment that offers for sale <br/>
<a id="pl.23.28"></a><var>23.28</var>methamphetamine precursor drugs who sells such a drug to any person in a suspicious <br/>
<a id="pl.23.29"></a><var>23.29</var>transaction shall report the transaction to the owner, supervisor, or manager of the <br/>
<a id="pl.23.30"></a><var>23.30</var>establishment. The owner, supervisor, or manager may report the transaction to local law <br/>
<a id="pl.23.31"></a><var>23.31</var>enforcement. A person who reports information under this subdivision in good faith is <br/>
<a id="pl.23.32"></a><var>23.32</var>immune from civil liability relating to the report.<br/>
<a id="pl.23.33"></a><var>23.33</var>(k) Paragraphs (b) to (j) do not apply to:<br/>
<a id="pl.23.34"></a><var>23.34</var>(1) pediatric products labeled pursuant to federal regulation primarily intended for <br/>
<a id="pl.23.35"></a><var>23.35</var>administration to children under 12 years of age according to label instructions;<br/>
<a id="pl.24.1"></a><var>24.1</var>(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as <br/>
<a id="pl.24.2"></a><var>24.2</var>being manufactured in a manner that prevents the drug from being used to manufacture <br/>
<a id="pl.24.3"></a><var>24.3</var>methamphetamine;<br/>
<a id="pl.24.4"></a><var>24.4</var>(3) methamphetamine precursor drugs in gel capsule or liquid form; or<br/>
<a id="pl.24.5"></a><var>24.5</var>(4) compounds, mixtures, or preparations in powder form where pseudoephedrine <br/>
<a id="pl.24.6"></a><var>24.6</var>constitutes less than one percent of its total weight and is not its sole active ingredient.<br/>
<a id="pl.24.7"></a><var>24.7</var>(l) The Board of Pharmacy, in consultation with the Department of Public Safety, <br/>
<a id="pl.24.8"></a><var>24.8</var>shall certify methamphetamine precursor drugs that meet the requirements of paragraph <br/>
<a id="pl.24.9"></a><var>24.9</var>(k), clause (2), and publish an annual listing of these drugs.<br/>
<a id="pl.24.10"></a><var>24.10</var>(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy <br/>
<a id="pl.24.11"></a><var>24.11</var>pursuant to sections 
         <statute_ref>151.42</statute_ref> to 
         <statute_ref>151.51</statute_ref> and registered with and regulated by the United <br/>
<a id="pl.24.12"></a><var>24.12</var>States Drug Enforcement Administration are exempt from the methamphetamine precursor <br/>
<a id="pl.24.13"></a><var>24.13</var>drug storage requirements of this section.<br/>
<a id="pl.24.14"></a><var>24.14</var>(n) This section preempts all local ordinances or regulations governing the sale <br/>
<a id="pl.24.15"></a><var>24.15</var>by a business establishment of over-the-counter products containing ephedrine or <br/>
<a id="pl.24.16"></a><var>24.16</var>pseudoephedrine. All ordinances enacted prior to the effective date of this act are void.<br/>
<a id="pl.24.17"></a><var>24.17</var>    Subd. 7. <b>Board of Pharmacy; regulation of substances.</b> The Board of Pharmacy <br/>
<a id="pl.24.18"></a><var>24.18</var>is authorized to regulate and define additional substances which contain quantities of a <br/>
<a id="pl.24.19"></a><var>24.19</var>substance possessing abuse potential in accordance with the following criteria:<br/>
<a id="pl.24.20"></a><var>24.20</var>(1) The Board of Pharmacy shall place a substance in Schedule I if it finds that the <br/>
<a id="pl.24.21"></a><var>24.21</var>substance has: A high potential for abuse, no currently accepted medical use in the United <br/>
<a id="pl.24.22"></a><var>24.22</var>States, and a lack of accepted safety for use under medical supervision.<br/>
<a id="pl.24.23"></a><var>24.23</var>(2) The Board of Pharmacy shall place a substance in Schedule II if it finds that the <br/>
<a id="pl.24.24"></a><var>24.24</var>substance has: A high potential for abuse, currently accepted medical use in the United <br/>
<a id="pl.24.25"></a><var>24.25</var>States, or currently accepted medical use with severe restrictions, and that abuse may lead <br/>
<a id="pl.24.26"></a><var>24.26</var>to severe psychological or physical dependence.<br/>
<a id="pl.24.27"></a><var>24.27</var>(3) The Board of Pharmacy shall place a substance in Schedule III if it finds that the <br/>
<a id="pl.24.28"></a><var>24.28</var>substance has: A potential for abuse less than the substances listed in Schedules I and II, <br/>
<a id="pl.24.29"></a><var>24.29</var>currently accepted medical use in treatment in the United States, and that abuse may lead <br/>
<a id="pl.24.30"></a><var>24.30</var>to moderate or low physical dependence or high psychological dependence.<br/>
<a id="pl.24.31"></a><var>24.31</var>(4) The Board of Pharmacy shall place a substance in Schedule IV if it finds that <br/>
<a id="pl.24.32"></a><var>24.32</var>the substance has: A low potential for abuse relative to the substances in Schedule III, <br/>
<a id="pl.24.33"></a><var>24.33</var>currently accepted medical use in treatment in the United States, and that abuse may lead <br/>
<a id="pl.24.34"></a><var>24.34</var>to limited physical dependence or psychological dependence relative to the substances in <br/>
<a id="pl.24.35"></a><var>24.35</var>Schedule III.<br/>
<a id="pl.25.1"></a><var>25.1</var>(5) The Board of Pharmacy shall place a substance in Schedule V if it finds that the <br/>
<a id="pl.25.2"></a><var>25.2</var>substance has: A low potential for abuse relative to the substances listed in Schedule IV, <br/>
<a id="pl.25.3"></a><var>25.3</var>currently accepted medical use in treatment in the United States, and limited physical <br/>
<a id="pl.25.4"></a><var>25.4</var>dependence and/or psychological dependence liability relative to the substances listed <br/>
<a id="pl.25.5"></a><var>25.5</var>in Schedule IV.<br/>
<a id="pl.25.6"></a><var>25.6</var>    Subd. 8. <b>Add, delete, or reschedule substances.</b> The state Board of Pharmacy may, <br/>
<a id="pl.25.7"></a><var>25.7</var>by rule, add substances to or delete or reschedule substances listed in this section. The <br/>
<a id="pl.25.8"></a><var>25.8</var>Board of Pharmacy may not delete or reschedule a drug that is in Schedule I, except as <br/>
<a id="pl.25.9"></a><var>25.9</var>provided in subdivision 12.<br/>
<a id="pl.25.10"></a><var>25.10</var>In making a determination regarding a substance, the Board of Pharmacy shall <br/>
<a id="pl.25.11"></a><var>25.11</var>consider the following: The actual or relative potential for abuse, the scientific evidence <br/>
<a id="pl.25.12"></a><var>25.12</var>of its pharmacological effect, if known, the state of current scientific knowledge <br/>
<a id="pl.25.13"></a><var>25.13</var>regarding the substance, the history and current pattern of abuse, the scope, duration, <br/>
<a id="pl.25.14"></a><var>25.14</var>and significance of abuse, the risk to public health, the potential of the substance to <br/>
<a id="pl.25.15"></a><var>25.15</var>produce psychic or physiological dependence liability, and whether the substance is an <br/>
<a id="pl.25.16"></a><var>25.16</var>immediate precursor of a substance already controlled under this section. The state Board <br/>
<a id="pl.25.17"></a><var>25.17</var>of Pharmacy may include any nonnarcotic drug authorized by federal law for medicinal <br/>
<a id="pl.25.18"></a><var>25.18</var>use in a schedule only if such drug must, under either federal or state law or rule, be <br/>
<a id="pl.25.19"></a><var>25.19</var>sold only on prescription.<br/>
<a id="pl.25.20"></a><var>25.20</var>    Subd. 8a. <b>Methamphetamine precursors</b><b>.</b> The State Board of Pharmacy may, <br/>
<a id="pl.25.21"></a><var>25.21</var>by order, require that nonprescription ephedrine or pseudophedrine products sold in <br/>
<a id="pl.25.22"></a><var>25.22</var>gel capsule or liquid form be subject to the sale restrictions established in subdivision <br/>
<a id="pl.25.23"></a><var>25.23</var>6 for methamphetamine precursor drugs, if the board concludes that ephedrine or <br/>
<a id="pl.25.24"></a><var>25.24</var>pseudophedrine products in gel capsule or liquid form can be used to manufacture <br/>
<a id="pl.25.25"></a><var>25.25</var>methamphetamine. In assessing the need for an order under this subdivision, the board <br/>
<a id="pl.25.26"></a><var>25.26</var>shall consult at least annually with the advisory council on controlled substances, the <br/>
<a id="pl.25.27"></a><var>25.27</var>commissioner of public safety, and the commissioner of health.<br/>
<a id="pl.25.28"></a><var>25.28</var>    Subd. 9. <b>Except substances by rule.</b> The state Board of Pharmacy may by rule <br/>
<a id="pl.25.29"></a><var>25.29</var>except any compound, mixture, or preparation containing any stimulant or depressant <br/>
<a id="pl.25.30"></a><var>25.30</var>substance listed in subdivision 4, clauses (1) and (2) paragraphs (b) and (c), or in <br/>
<a id="pl.25.31"></a><var>25.31</var>subdivisions 5 and 6 from the application of all or any part of this chapter, if the <br/>
<a id="pl.25.32"></a><var>25.32</var>compound, mixture, or preparation contains one or more active medicinal ingredients not <br/>
<a id="pl.25.33"></a><var>25.33</var>having a stimulant or depressant effect on the central nervous system; provided, that <br/>
<a id="pl.25.34"></a><var>25.34</var>such admixtures shall be included therein in such combinations, quantity, proportion, <br/>
<a id="pl.25.35"></a><var>25.35</var>or concentration as to vitiate the potential for abuse of the substances which do have a <br/>
<a id="pl.25.36"></a><var>25.36</var>stimulant or depressant effect on the central nervous system.<br/>
<a id="pl.26.1"></a><var>26.1</var>    Subd. 10. <b>Dextromethorphan.</b> Dextromethorphan shall not be deemed to be <br/>
<a id="pl.26.2"></a><var>26.2</var>included in any schedule by reason of the enactment of Laws 1971, chapter 937, unless <br/>
<a id="pl.26.3"></a><var>26.3</var>controlled pursuant to the foregoing provisions of this section.<br/>
<a id="pl.26.4"></a><var>26.4</var>    Subd. 12. <b>Coordination of controlled substance regulation with federal law and </b><br/>
<a id="pl.26.5"></a><var>26.5</var><b>state statute.</b> If any substance is designated, rescheduled, or deleted as a controlled <br/>
<a id="pl.26.6"></a><var>26.6</var>substance under federal law and notice thereof is given to the state Board of Pharmacy, the <br/>
<a id="pl.26.7"></a><var>26.7</var>state Board of Pharmacy shall similarly control the substance under this chapter, after the <br/>
<a id="pl.26.8"></a><var>26.8</var>expiration of 30 days from publication in the Federal Register of a final order designating <br/>
<a id="pl.26.9"></a><var>26.9</var>a substance as a controlled substance or rescheduling or deleting a substance. Such order <br/>
<a id="pl.26.10"></a><var>26.10</var>shall be filed with the secretary of state. If within that 30-day period, the state Board of <br/>
<a id="pl.26.11"></a><var>26.11</var>Pharmacy objects to inclusion, rescheduling, or deletion, it shall publish the reasons for <br/>
<a id="pl.26.12"></a><var>26.12</var>objection and afford all interested parties an opportunity to be heard. At the conclusion of <br/>
<a id="pl.26.13"></a><var>26.13</var>the hearing, the state Board of Pharmacy shall publish its decision, which shall be subject <br/>
<a id="pl.26.14"></a><var>26.14</var>to the provisions of chapter 14.<br/>
<a id="pl.26.15"></a><var>26.15</var>In exercising the authority granted by this chapter, the state Board of Pharmacy shall <br/>
<a id="pl.26.16"></a><var>26.16</var>be subject to the provisions of chapter 14. The state Board of Pharmacy shall provide <br/>
<a id="pl.26.17"></a><var>26.17</var>copies of any proposed rule under this chapter to the advisory council on controlled <br/>
<a id="pl.26.18"></a><var>26.18</var>substances at least 30 days prior to any hearing required by section 
<statute_ref>14.14, subdivision 1</statute_ref>. <br/>
<a id="pl.26.19"></a><var>26.19</var>The state Board of Pharmacy shall consider the recommendations of the advisory council <br/>
<a id="pl.26.20"></a><var>26.20</var>on controlled substances, which may be made prior to or at the hearing.<br/>
<a id="pl.26.21"></a><var>26.21</var>The state Board of Pharmacy shall annually submit a report to the legislature on or <br/>
<a id="pl.26.22"></a><var>26.22</var>before December 1 that specifies what changes the board made to the controlled substance <br/>
<a id="pl.26.23"></a><var>26.23</var>schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in <br/>
<a id="pl.26.24"></a><var>26.24</var>the preceding 12 months. The report must include specific recommendations for amending <br/>
<a id="pl.26.25"></a><var>26.25</var>the controlled substance schedules contained in subdivisions 2 to 6, so that they conform <br/>
<a id="pl.26.26"></a><var>26.26</var>with the controlled substance schedules maintained by the board in Minnesota Rules, <br/>
<a id="pl.26.27"></a><var>26.27</var>parts 6800.4210 to 6800.4250.<br/>
<a id="pl.26.28"></a><var>26.28</var>    Subd. 13. <b>Implementation study.</b> Annually, the state Board of Pharmacy shall study <br/>
<a id="pl.26.29"></a><var>26.29</var>the implementation of this chapter in relation to the problems of drug abuse in Minnesota.<br/>
<a id="pl.26.30"></a><var>26.30</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2012, and applies to crimes <br/>
<a id="pl.26.31"></a><var>26.31</var>committed on or after that date.<br/>
<br/>
<a id="bill.0.2.0"></a><a id="pl.26.32"></a><var>26.32</var>    Sec. 2. Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6, is <br/>
<a id="pl.26.33"></a><var>26.33</var>amended to read:<br/>
<a id="pl.27.1"></a><var>27.1</var>    Subd. 6. <b>Sale or possession of synthetic cannabinoids.</b> (a) As used in this <br/>
<a id="pl.27.2"></a><var>27.2</var>subdivision, "synthetic cannabinoid" includes any substance included in section 
         <statute_ref>152.02</statute_ref>, <br/>
<a id="pl.27.3"></a><var>27.3</var>subdivision 2, paragraph (h), clause (7) (3).<br/>
<a id="pl.27.4"></a><var>27.4</var>(b) A person who unlawfully sells a synthetic cannabinoid for no remuneration is <br/>
<a id="pl.27.5"></a><var>27.5</var>guilty of a gross misdemeanor.<br/>
<a id="pl.27.6"></a><var>27.6</var>(c) A person who unlawfully sells any amount of a synthetic cannabinoid is guilty of <br/>
<a id="pl.27.7"></a><var>27.7</var>a gross misdemeanor felony and if convicted may be sentenced to imprisonment for not <br/>
<a id="pl.27.8"></a><var>27.8</var>more than five years or to payment of a fine of not more than $10,000, or both.<br/>
<a id="pl.27.9"></a><var>27.9</var>(c) (d) A person who unlawfully possesses any amount of a synthetic cannabinoid is <br/>
<a id="pl.27.10"></a><var>27.10</var>guilty of a misdemeanor.<br/>
<a id="pl.27.11"></a><var>27.11</var>(d) (e) Notwithstanding any contrary provision in sections 
         <statute_ref>152.021</statute_ref> to 
         <statute_ref>152.025</statute_ref>, this <br/>
<a id="pl.27.12"></a><var>27.12</var>subdivision describes the exclusive penalties for the sale and possession of synthetic <br/>
<a id="pl.27.13"></a><var>27.13</var>cannabinoid.<br/>
<a id="pl.27.14"></a><var>27.14</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2012, and applies to crimes <br/>
<a id="pl.27.15"></a><var>27.15</var>committed on or after that date.<br/>
<br/>
<a id="bill.0.3.0"></a><a id="pl.27.16"></a><var>27.16</var>    Sec. 3. Minnesota Statutes 2010, section 152.18, subdivision 1, is amended to read:<br/>
<a id="pl.27.17"></a><var>27.17</var>    Subdivision 1. <b>Deferring prosecution for certain first time drug offenders.</b> If <br/>
<a id="pl.27.18"></a><var>27.18</var>any person who has not previously participated in or completed a diversion program <br/>
<a id="pl.27.19"></a><var>27.19</var>authorized under section 
         <statute_ref>401.065</statute_ref> or who has not previously been placed on probation <br/>
<a id="pl.27.20"></a><var>27.20</var>without a judgment of guilty and thereafter been discharged from probation under <br/>
<a id="pl.27.21"></a><var>27.21</var>this section is found guilty of a violation of section 
         <statute_ref>152.024, subdivision 2</statute_ref>, 
         <statute_ref>152.025, <br/>
<a id="pl.27.22"></a><var>27.22</var>subdivision 2
         </statute_ref>, or 
         <statute_ref>152.027, subdivision 2</statute_ref>, 3, or 4, or 6, paragraph (d), for possession of a <br/>
<a id="pl.27.23"></a><var>27.23</var>controlled substance, after trial or upon a plea of guilty, and the court determines that the <br/>
<a id="pl.27.24"></a><var>27.24</var>violation does not qualify as a subsequent controlled substance conviction under section <br/>
<statute_ref><a id="pl.27.25"></a><var>27.25</var>152.01, subdivision 16a
         </statute_ref>, the court may, without entering a judgment of guilty and with the <br/>
<a id="pl.27.26"></a><var>27.26</var>consent of the person, defer further proceedings and place the person on probation upon <br/>
<a id="pl.27.27"></a><var>27.27</var>such reasonable conditions as it may require and for a period, not to exceed the maximum <br/>
<a id="pl.27.28"></a><var>27.28</var>sentence provided for the violation. The court may give the person the opportunity to <br/>
<a id="pl.27.29"></a><var>27.29</var>attend and participate in an appropriate program of education regarding the nature and <br/>
<a id="pl.27.30"></a><var>27.30</var>effects of alcohol and drug abuse as a stipulation of probation. Upon violation of a <br/>
<a id="pl.27.31"></a><var>27.31</var>condition of the probation, the court may enter an adjudication of guilt and proceed as <br/>
<a id="pl.27.32"></a><var>27.32</var>otherwise provided. The court may, in its discretion, dismiss the proceedings against the <br/>
<a id="pl.27.33"></a><var>27.33</var>person and discharge the person from probation before the expiration of the maximum <br/>
<a id="pl.27.34"></a><var>27.34</var>period prescribed for the person's probation. If during the period of probation the person <br/>
<a id="pl.27.35"></a><var>27.35</var>does not violate any of the conditions of the probation, then upon expiration of the period <br/>
<a id="pl.28.1"></a><var>28.1</var>the court shall discharge the person and dismiss the proceedings against that person. <br/>
<a id="pl.28.2"></a><var>28.2</var>Discharge and dismissal under this subdivision shall be without court adjudication of guilt, <br/>
<a id="pl.28.3"></a><var>28.3</var>but a not public record of it shall be retained by the Bureau of Criminal Apprehension <br/>
<a id="pl.28.4"></a><var>28.4</var>for the purpose of use by the courts in determining the merits of subsequent proceedings <br/>
<a id="pl.28.5"></a><var>28.5</var>against the person. The not public record may also be opened only upon court order for <br/>
<a id="pl.28.6"></a><var>28.6</var>purposes of a criminal investigation, prosecution, or sentencing. Upon request by law <br/>
<a id="pl.28.7"></a><var>28.7</var>enforcement, prosecution, or corrections authorities, the bureau shall notify the requesting <br/>
<a id="pl.28.8"></a><var>28.8</var>party of the existence of the not public record and the right to seek a court order to open it <br/>
<a id="pl.28.9"></a><var>28.9</var>pursuant to this section. The court shall forward a record of any discharge and dismissal <br/>
<a id="pl.28.10"></a><var>28.10</var>under this subdivision to the bureau which shall make and maintain the not public record <br/>
<a id="pl.28.11"></a><var>28.11</var>of it as provided under this subdivision. The discharge or dismissal shall not be deemed a <br/>
<a id="pl.28.12"></a><var>28.12</var>conviction for purposes of disqualifications or disabilities imposed by law upon conviction <br/>
<a id="pl.28.13"></a><var>28.13</var>of a crime or for any other purpose.<br/>
<a id="pl.28.14"></a><var>28.14</var>For purposes of this subdivision, "not public" has the meaning given in section <br/>
<statute_ref><a id="pl.28.15"></a><var>28.15</var>13.02, subdivision 8a
         </statute_ref>.<br/>
<a id="pl.28.16"></a><var>28.16</var><b>EFFECTIVE DATE.</b>This section is effective August 1, 2012, and applies to crimes <br/>
<a id="pl.28.17"></a><var>28.17</var>committed on or after that date.<br/>